株探米国株
日本語 英語
エドガーで原本を確認する
0001099219false00010992192023-05-032023-05-030001099219us-gaap:CommonStockMember2023-05-032023-05-030001099219us-gaap:SeriesAPreferredStockMember2023-05-032023-05-030001099219us-gaap:SeriesEPreferredStockMember2023-05-032023-05-030001099219us-gaap:SeriesFPreferredStockMember2023-05-032023-05-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549  
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 3, 2023
METLIFE, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
 
1-15787 13-4075851
(Commission File Number) (IRS Employer Identification No.)
200 Park Avenue, New York, NY 10166-0188
(Address of Principal Executive Offices) (Zip Code)
(212) 578-9500
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report) 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.01 MET New York Stock Exchange
Floating Rate Non-Cumulative Preferred Stock,
Series A, par value $0.01
MET PRA New York Stock Exchange
Depositary Shares, each representing a 1/1,000th
interest in a share of 5.625% Non-Cumulative
Preferred Stock, Series E
MET PRE New York Stock Exchange
Depositary Shares, each representing a 1/1,000th interest in a share of 4.75% Non-Cumulative Preferred Stock, Series F MET PRF
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company    ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐



Item 2.02 Results of Operations and Financial Condition.
On May 3, 2023, MetLife, Inc. issued (i) a news release announcing its results for the quarter ended March 31, 2023 (the “Earnings Release”), a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference, (ii) a Quarterly Financial Supplement for the quarter ended March 31, 2023 (the “Quarterly Financial Supplement”), a copy of which is attached hereto as Exhibit 99.2 and is incorporated herein by reference and (iii) a fact sheet setting forth its total assets under management as of March 31, 2023 (the "Total AUM Fact Sheet"), a copy of which is attached hereto as Exhibit 99.3 and is incorporated herein by reference.
The Earnings Release and the Quarterly Financial Supplement are furnished and not filed pursuant to instruction B.2 of Form 8-K. The foregoing description of the Total AUM Fact Sheet is not complete and is qualified in its entirety by reference to the Total AUM Fact Sheet, which is filed as Exhibit 99.3.
Item 7.01 Regulation FD Disclosure.
On May 3, 2023, MetLife, Inc. issued a supplemental slide presentation for the quarter ended March 31, 2023 (the “Supplemental Slides”), a copy of which is attached hereto as Exhibit 99.4 and is incorporated herein by reference. The slides highlight information in MetLife, Inc.’s Earnings Release and Quarterly Financial Supplement, as well as other prior public disclosures. The Supplemental Slides are furnished and not filed pursuant to instruction B.2 of Form 8-K.
Item 8.01 Other Events.
On May 3, 2023, MetLife, Inc. announced that its Board of Directors approved a new $3 billion authorization to repurchase its common stock.
The text of Item 2.02 above with respect to the Total AUM Fact Sheet is incorporated herein by reference.
2


Item 9.01 Financial Statements and Exhibits.

101 Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (Inline eXtensible Business Reporting Language)
104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101)
3


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
METLIFE, INC.
By: /s/ Tamara L. Schock
Name: Tamara L. Schock
Title: Executive Vice President and
Chief Accounting Officer
Date: May 3, 2023
4
EX-99.1 2 ex991earningsreleasetables.htm EX-99.1 Document

Exhibit 99.1

mllogonewa22.jpg
                    For Immediate Release İ Global Communications İ MetLife, Inc.


METLIFE ANNOUNCES FIRST QUARTER 2023 RESULTS
NEW YORK, May 3, 2023 - MetLife, Inc. (NYSE: MET) today announced its first quarter 2023 results.
First Quarter Results Summary*
•Net income of $14 million, or $0.02 per share, compared to net income of $1.6 billion, or $1.89 per share, in the first quarter of 2022.
•Adjusted earnings of $1.2 billion, or $1.52 per share, compared to adjusted earnings of $1.7 billion, or $2.04 per share, in the first quarter of 2022.
•Book value of $36.89 per share, down 22 percent from $47.39 per share at March 31, 2022.
•Book value, excluding accumulated other comprehensive income (AOCI) other than foreign currency translation adjustments (FCTA), of $53.83 per share, up 2 percent from $52.97 per share at March 31, 2022.
•Return on equity (ROE) of 0.2 percent.
•Adjusted ROE, excluding AOCI other than FCTA, of 11.3 percent.
•Holding company cash and liquid assets of $4.2 billion at March 31, 2023, which is above the target cash buffer of $3.0 - $4.0 billion.



Commenting on the company’s results, MetLife President and CEO Michel Khalaf said: “While 2023 is shaping up to be another year of uncertainty, the successful actions we’ve taken to focus, simplify and differentiate our business are reflected in this quarter’s strong underlying business fundamentals. We remain focused on managing risk across economic cycles and controlling what we can to deliver for our shareholders and our stakeholders.”








*Long-Duration Targeted Improvements (LDTI)
Financial results presented in this news release reflect LDTI accounting, pursuant to Financial Accounting Standards Board Accounting Standards Update No. 2018-12, which became effective on January 1, 2023. For more information, refer to "Non-GAAP and Other Financial Disclosures."

Page 1 of 24



First Quarter 2023 Summary
($ in millions, except per share data)
Three months ended
March 31,
2023 2022 Change
Premiums, fees and other revenues $ 11,517 $ 12,589 (9)%
Net investment income
4,645 4,284 8%
Net investment gains (losses)
(684) (517)
Net derivative gains (losses)
(90) (951)
Total revenues
$ 15,388 $ 15,405
Adjusted premiums, fees and other revenues
$ 11,520 $ 12,487 (8)%
Adjusted premiums, fees and other revenues, excluding pension risk transfers (PRT) $ 11,541 $ 11,229 3%
Net income (loss)
$ 14 $ 1,571 (99)%
Net income (loss) per share
$ 0.02 $ 1.89 (99)%
Adjusted earnings
$ 1,184 $ 1,695 (30)%
Adjusted earnings per share
$ 1.52 $ 2.04 (25)%
Adjusted earnings, excluding total notable items
$ 1,184 $ 1,695 (30)%
Adjusted earnings, excluding total notable items per share
$ 1.52 $ 2.04 (25)%
Book value per share
$ 36.89 $ 47.39 (22)%
Book value per share, excluding AOCI other than FCTA
$ 53.83 $ 52.97 2%
Expense ratio
20.3  % 18.0  %    
Direct expense ratio, excluding total notable items related to direct expenses and PRT
12.0  % 11.9  %
Adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT 20.0  % 19.5  %
ROE
0.2  % 14.9  %
Adjusted ROE, excluding AOCI other than FCTA
11.3  % 15.7  %
Adjusted ROE, excluding total notable items (excludes AOCI other than FCTA)
11.3  % 15.7  %
Information regarding the non-GAAP and other financial measures included in this news release and reconciliation of the non-GAAP financial measures to GAAP measures are in “Non-GAAP and Other Financial Disclosures” below and in the tables that accompany this news release.

Supplemental slides for the first quarter of 2023, titled “1Q23 Supplemental Slides,” are available on the MetLife Investor Relations website at https://investor.metlife.com and in the Form 8-K furnished by MetLife to the U.S. Securities and Exchange Commission in connection with this earnings release. Supplemental information about MetLife's diversified global investment portfolio is contained in the "1Q23 - General Account Assets Under Management Fact Sheet," available on the above-mentioned website.


Page 2 of 24




Total Company Discussion
MetLife reported first quarter 2023 premiums, fees and other revenues of $11.5 billion, down 9 percent from the first quarter of 2022. Adjusted premiums, fees and other revenues were $11.5 billion, down 8 percent on a reported basis and down 6 percent on a constant currency basis from the prior-year period, which included $1.3 billion of pension risk transfer sales.
Net investment income was $4.6 billion, up 8 percent from the first quarter of 2022, driven by increases in the estimated fair value of certain securities which do not qualify as separate accounts under GAAP. Adjusted net investment income was $4.6 billion, down 8 percent from the prior-year period, largely driven by lower variable investment income.
Net investment losses were $684 million, primarily driven by the opportunistic repositioning of fixed maturity securities in Japan and the strengthening of mortgage loan allowance for credit loss in the quarter, reflecting the current environment. Net derivative losses amounted to $90 million, or $71 million after tax during the quarter, driven by a strengthening of equity markets.
Net income was $14 million, primarily driven by net investment losses, compared to net income of $1.6 billion in the first quarter of 2022. On a per share basis, net income was $0.02, compared to net income of $1.89 in the prior-year period.
MetLife reported adjusted earnings of $1.2 billion, down 30 percent on a reported basis and down 29 percent on a constant currency basis from the first quarter of 2022. On a per share basis, adjusted earnings were $1.52, down 25 percent from the prior-year period.

Adjusted Earnings by Segment Summary*
Three months ended
March 31, 2023
Segment Change from
prior-year period
Change from
prior-year
period (on a
constant
currency
basis)
U.S. 7%
Asia (53)% (52)%
Latin America 59% 51%
Europe, the Middle East and Africa (EMEA)
9% 30%
MetLife Holdings (55)%
*The percentages in this table are on a reported and constant currency basis.


Business Discussions
All comparisons of the results for the first quarter of 2023 in the business discussions that follow are with the first quarter of 2022, unless otherwise noted. There were no notable items in the first quarter of 2023, as indicated in the notable items table which follows the Business Discussions section of this release.
Page 3 of 24



U.S.
($ in millions) Three months ended March 31, 2023 Three months ended March 31, 2022 Change
Adjusted earnings
$707 $663 7%
Adjusted premiums, fees and other revenues
$6,697 $7,729 (13)%
Adjusted premiums, fees and other revenues, excluding PRT
$6,718 $6,471 4%
Notable item(s)
$0 $0

•Adjusted earnings were $707 million, up 7 percent, primarily driven by favorable underwriting, recurring interest margins, and volume growth, partially offset by lower variable investment income.
•Adjusted premiums, fees and other revenues were $6.7 billion, down 13 percent, driven by higher pension risk transfer sales in the prior-year period, partially offset by solid growth in Group Benefits.


Group Benefits
($ in millions) Three months ended March 31, 2023 Three months ended March 31, 2022 Change
Adjusted earnings
$307 $117 162%
Adjusted premiums, fees and other revenues
$6,049 $6,004 1%
Notable item(s) $0 $0

•Adjusted earnings were $307 million, up 162 percent, primarily driven by favorable underwriting and volume growth.
•Adjusted premiums, fees and other revenues were $6.0 billion, up 1 percent, driven by solid underlying growth across most products, including voluntary, mostly offset by higher premiums in the prior-year period related to participating life contracts. Premiums, fees and other revenues from participating life contracts can fluctuate with claims experience.
•Sales were up 15 percent, driven by strong growth across all market segments.









Page 4 of 24



Retirement and Income Solutions
($ in millions) Three months ended March 31, 2023 Three months ended March 31, 2022 Change
Adjusted earnings
$400 $546 (27)%
Adjusted premiums, fees and other revenues
$648 $1,725 (62)%
Adjusted premiums, fees and other revenues, excluding PRT
$669 $467 43%
Notable item(s) $0 $0  

•Adjusted earnings were $400 million, down 27 percent, largely driven by lower variable investment income, partially offset by recurring interest margins.
•Adjusted premiums, fees and other revenues were $648 million, down 62 percent, largely driven by higher pension risk transfer sales in the prior-year period.
•Excluding pension risk transfers, adjusted premiums, fees and other revenues were $669 million, up 43 percent, primarily driven by strong structured settlement sales and growth in UK longevity reinsurance.
•Sales were down 54 percent, primarily due to lower stable value and pension risk transfer sales, partially offset by strong structured settlement sales.


ASIA
($ in millions) Three months ended March 31, 2023 Three months ended March 31, 2022 Change
Adjusted earnings $280 $599 (53)%
Adjusted earnings (constant currency)
$280 $581 (52)%
Adjusted premiums, fees and other revenues
$1,794 $1,976 (9)%
Notable item(s) $0 $0
Asia general account assets under management (at amortized cost) $127,120 $129,935 (2)%

•Adjusted earnings were $280 million, down 53 percent on a reported basis, and down 52 percent on a constant currency basis, largely driven by lower variable investment income.
•Adjusted premiums, fees and other revenues were $1.8 billion, down 9 percent, and essentially flat on a constant currency basis.
•Asia general account assets under management (at amortized cost) were $127.1 billion, down 2 percent, and up 3 percent on a constant currency basis.
•Sales were $653 million, up 18 percent on a constant currency basis, driven by strong sales across the region, particularly in Japan.




Page 5 of 24



LATIN AMERICA
($ in millions) Three months ended March 31, 2023 Three months ended March 31, 2022 Change
Adjusted earnings $215 $135 59%
Adjusted earnings (constant currency)
$215 $142 51%
Adjusted premiums, fees and other revenues
$1,372 $1,036 32%
Notable item(s) $0 $0

•Adjusted earnings were $215 million, up 59 percent on a reported basis, and up 51 percent on a constant currency basis, primarily driven by favorable underwriting, recurring interest margins and volume growth. Lower variable investment income was a partial offset.
•Adjusted premiums, fees and other revenues were $1.4 billion, up 32 percent, and up 26 percent on a constant currency basis, driven by strong sales and solid persistency across the region.
•Sales were $398 million, up 36 percent on a constant currency basis, driven by growth across the region.

EMEA
($ in millions) Three months ended March 31, 2023 Three months ended March 31, 2022 Change
Adjusted earnings
$60 $55 9%
Adjusted earnings (constant currency)
$60 $46 30%
Adjusted premiums, fees and other revenues
$581 $601 (3)%
Notable item(s)
$0 $0

•Adjusted earnings were $60 million, up 9 percent on a reported basis, and up 30 percent on a constant currency basis, driven by higher recurring interest margins and volume growth.
•Adjusted premiums, fees and other revenues were $581 million, down 3 percent, and up 5 percent on a constant currency basis, primarily due to strong sales across the region.
•Sales were $266 million, up 27 percent on a constant currency basis, driven by growth across the region.





METLIFE HOLDINGS
Page 6 of 24



($ in millions) Three months ended March 31, 2023 Three months ended March 31, 2022 Change
Adjusted earnings
$158 $348 (55)%
Adjusted premiums, fees and other revenues
$959 $1,048 (8)%
Notable item(s)
$0 $0

•Adjusted earnings were $158 million, down 55 percent, largely driven by lower variable investment income.
•Adjusted premiums, fees and other revenues were $959 million, down 8 percent.

CORPORATE & OTHER
($ in millions) Three months ended March 31, 2023 Three months ended March 31, 2022 Change
Adjusted earnings $(236) $(105)
Notable item(s) $0 $0

•Adjusted loss of $236 million, compared to an adjusted loss of $105 million in the prior-year period, largely driven by lower variable investment income.

INVESTMENTS
($ in millions) Three months ended March 31, 2023 Three months ended March 31, 2022 Change
Adjusted net investment income
$4,606 $4,992 (8)%

•Adjusted net investment income was $4.6 billion, down 8 percent. Variable investment income was a loss of $44 million, compared to variable investment income of $1.2 billion in the prior-year period, primarily driven by returns on private equity and real estate equity funds. Higher interest rates and asset growth were partial offsets.

FIRST QUARTER 2023 NOTABLE ITEMS
($ in millions)
Adjusted Earnings
Three months ended March 31, 2023
Notable Items U.S. Asia Latin
America
EMEA MetLife
Holdings
Corporate
&
Other
Total
Group Benefits Retirement and Income Solutions
Total notable items $0 $0 $0 $0 $0 $0 $0 $0

###

Page 7 of 24




Contacts:     For Media:        Brian Blaser (212) 578-2415    
For Investors:         John Hall (212) 578-7888


About MetLife
MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates (“MetLife”), is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management to help individual and institutional customers build a more confident future. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Japan, Latin America, Asia, Europe and the Middle East. For more information, visit www.metlife.com.
Conference Call
MetLife will hold its first quarter 2023 earnings conference call and audio webcast on Thursday, May 4, 2023, from 9-10 a.m. (ET). The conference call will be available live via telephone and the internet. To listen via telephone, dial 877-692-8955 (U.S.) or 234-720-6979 (outside the U.S.). The participant access code is 2510803. To listen to the conference call via the internet, click the link to the webcast on the MetLife Investor Relations web page (https://investor.metlife.com). Those who want to listen to the call via telephone or the internet should dial in or go to the website at least 15 minutes prior to the call to register, and/or download and install any necessary audio software.

The conference call will be available for replay via telephone and the internet beginning at 11 a.m. (ET) on Thursday, May 4, 2023, until Thursday, May 11, 2023, at 11:59 p.m. (ET). To listen to a replay of the conference call via telephone, dial 866-207-1041 (U.S.) or 402-970-0847 (outside the U.S.). The access code for the replay is 5649808. To access the replay of the conference call over the internet, visit the above-mentioned website.
Non-GAAP and Other Financial Disclosures
Any references in this news release (except in this section and the tables that accompany this release) to: should be read as, respectively:
(i) net income (loss); (i)  net income (loss) available to MetLife, Inc.’s common shareholders;
(ii) net income (loss) per share; (ii) net income (loss) available to MetLife, Inc.’s common shareholders per diluted common share;
(iii) adjusted earnings; (iii) adjusted earnings available to common shareholders;
(iv) adjusted earnings per share; (iv) adjusted earnings available to common shareholders per diluted common share;
(v) book value per share; (v) book value per common share;
(vi) book value per share, excluding AOCI other than FCTA; (vi) book value per common share, excluding AOCI other than FCTA;
(vii) return on equity; and (vii) return on MetLife, Inc.’s common stockholders’ equity; and
Page 8 of 24



(viii) adjusted return on equity, excluding AOCI other than FCTA. (viii) adjusted return on MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA.
In this news release, MetLife presents certain measures of its performance on a consolidated and segment basis that are not calculated in accordance with accounting principles generally accepted in the United States of America (GAAP). MetLife believes that these non-GAAP financial measures enhance the understanding for MetLife and its investors of MetLife's performance by highlighting the results of operations and the underlying profitability drivers of the business. Segment-specific financial measures are calculated using only the portion of consolidated results attributable to that specific segment.

The following non-GAAP financial measures should not be viewed as substitutes for the most directly comparable financial measures calculated in accordance with GAAP:
Non-GAAP financial measures: Comparable GAAP financial measures:
(i) total adjusted revenues; (i) total revenues;
(ii) total adjusted expenses; (ii) total expenses;
(iii) adjusted premiums, fees and other revenues; (iii) premiums, fees and other revenues;
(iv) adjusted premiums, fees and other revenues, excluding PRT; (iv) premiums, fees and other revenues;
(v) adjusted net investment income; (v) net investment income
(vi) adjusted capitalization of deferred policy acquisition costs (DAC); (vi) capitalization of DAC;
(vii) adjusted earnings available to common shareholders; (vii) net income (loss) available to MetLife, Inc.’s common shareholders;
(viii) adjusted earnings available to common shareholders, excluding total notable items; (viii) net income (loss) available to MetLife, Inc.’s common shareholders;
(ix) adjusted earnings available to common shareholders per diluted common share; (ix) net income (loss) available to MetLife, Inc.’s common shareholders per diluted common share;
(x) adjusted earnings available to common shareholders, excluding total notable items, per diluted common share; (x) net income (loss) available to MetLife, Inc.’s common shareholders per diluted common share;
(xi) adjusted return on equity; (xi) return on equity;
(xii) adjusted return on equity, excluding AOCI other than FCTA; (xii) return on equity;
(xiii) adjusted return on equity, excluding total notable items (excludes AOCI other than FCTA); (xiii) return on equity;
(xiv) investment portfolio gains (losses); (xiv) net investment gains (losses);
(xv) derivative gains (losses); (xv) net derivative gains (losses);
(xvi) total MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA; (xvi) total MetLife, Inc.’s stockholders’ equity;
(xvii) total MetLife, Inc.’s common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA); (xvii) total MetLife, Inc.’s stockholders’ equity;
(xviii) book value per common share, excluding AOCI other than FCTA; (xviii) book value per common share;
Page 9 of 24



(xix) free cash flow of all holding companies; (xix) MetLife, Inc. (parent company only) net cash provided by (used in) operating activities;
(xx) adjusted other expenses; (xx) other expenses;
(xxi) adjusted other expenses, net of adjusted capitalization of DAC; (xxi) other expenses, net of capitalization of DAC;
(xxii) adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses; (xxii) other expenses, net of capitalization of DAC;
(xxiii) adjusted expense ratio; (xxiii) expense ratio;
(xxiv) adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT; (xxiv) expense ratio;
(xxv) direct expenses; (xxv) other expenses;
(xxvi) direct expenses, excluding total notable items related to direct expenses; (xxvi) other expenses;
(xxvii) direct expense ratio; and (xxvii) expense ratio; and
(xxviii) direct expense ratio, excluding total notable items related to direct expenses and PRT. (xxviii) expense ratio.

Any of these financial measures shown on a constant currency basis reflect the impact of changes in foreign currency exchange rates and are calculated using the average foreign currency exchange rates for the most recent period. As a result, comparable prior period amounts are updated each period to reflect the most recent period average currency exchange rates.
Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in this earnings news release and in this period’s quarterly financial supplement, which is available at www.metlife.com.

MetLife’s definitions of non-GAAP and other financial measures discussed in this news release may differ from those used by other companies:
Adjusted earnings and related measures
•adjusted earnings;
•adjusted earnings available to common shareholders;
•adjusted earnings available to common shareholders on a constant currency basis;
•adjusted earnings available to common shareholders, excluding total notable items;
•adjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis;
•adjusted earnings available to common shareholders per diluted common share;
•adjusted earnings available to common shareholders on a constant currency basis per diluted common share;
•adjusted earnings available to common shareholders, excluding total notable items per diluted common share; and
•adjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis per diluted common share.

These measures are used by management to evaluate performance and allocate resources. Consistent with GAAP guidance for segment reporting, adjusted earnings and components of, or other financial measures based on, adjusted earnings are also MetLife’s GAAP measures of segment performance. Adjusted earnings and other financial measures based on adjusted earnings are also the measures by which MetLife senior management’s and many other employees’ performance is evaluated for the purposes of determining their compensation under applicable compensation plans.
Page 10 of 24



Adjusted earnings and other financial measures based on adjusted earnings allow analysis of MetLife's performance relative to its business plan and facilitate comparisons to industry results.


Effective January 1, 2023, MetLife adopted ASU 2018-12, Financial Services - Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts, as amended ("LDTI"), with a transition date of January 1, 2021, which impacted the calculation of adjusted earnings. Due to the adoption of LDTI, the measurement model was simplified for DAC and VOBA, and most embedded derivatives were reclassified as market risk benefits. As a result, MetLife updated its calculation of adjusted earnings to remove certain adjustments related to the amortization of DAC, VOBA and related intangibles and adjusted for changes in measurement of certain guarantees. Under LDTI, adjusted earnings excludes changes in fair value associated with market risk benefits, changes in discount rates on certain annuitization guarantees, losses at contract inception for certain single premium business, and asymmetrical accounting associated with in-force reinsurance. All periods presented herein reflect the updated calculation of adjusted earnings.
Adjusted earnings is defined as adjusted revenues less adjusted expenses, net of income tax. Adjusted earnings available to common shareholders is defined as adjusted earnings less preferred stock dividends.
Adjusted revenues and adjusted expenses
These financial measures, along with the related adjusted premiums, fees and other revenues, focus on our primary businesses principally by excluding the impact of (i) market volatility which could distort trends, (ii) asymmetrical and non-economic accounting, and (iii) revenues and costs related to divested businesses, non-core products and certain entities required to be consolidated under GAAP. Also, these measures exclude results of discontinued operations under GAAP.
Market volatility can have a significant impact on MetLife’s financial results. Adjusted earnings excludes net investment gains (losses), net derivative gains (losses), market risk benefits remeasurement gains (losses) and goodwill impairments. Further, policyholder benefits and claims exclude (i) changes in the discount rate on certain annuitization guarantees accounted for as additional liabilities and (ii) market value adjustments.
Asymmetrical and non-economic accounting adjustments are made to the line items indicated in calculating adjusted earnings:
•Net investment income includes earned income on derivatives and amortization of premium on derivatives that are hedges of investments or that are used to replicate certain investments, but do not qualify for hedge accounting treatment ("Investment hedge adjustments").
•Other revenues include settlements of foreign currency earnings hedges.
•Policyholder benefits and claims excludes (i) amortization of basis adjustments associated with de-designated fair value hedges of future policy benefits, (ii) inflation-indexed benefit adjustments associated with contracts backed by inflation-indexed investments, and (iii) non-economic losses incurred at contract inception for certain single premium annuity business. These losses are amortized into adjusted earnings within policyholder benefits and claims over the estimated lives of the contracts.
•Interest credited to policyholder account balances excludes amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass-through adjustments.
Divested businesses are those that have been or will be sold or exited by MetLife but do not meet the discontinued operations criteria under GAAP. Divested businesses also include the net impact of transactions with exited businesses that have been eliminated in consolidation under GAAP and costs relating to businesses that have been or will be sold or exited by MetLife that do not meet the criteria to be included in results of discontinued operations under GAAP.
Page 11 of 24



Other adjustments are made to the line items indicated in calculating adjusted earnings:
•Net investment income and interest credited to policyholder account balances excludes certain amounts related to contractholder-directed equity securities ("Unit-linked contract income") and ("Unit-linked contract costs").
•Other revenues include fee revenue on synthetic GICs accounted for as freestanding derivatives.
•Other revenues exclude and other expenses include fees received in connection with services provided under transition service agreements.
•Other expenses exclude (i) implementation of new insurance regulatory requirements and other costs, and (ii) acquisition, integration and other related costs. Other expenses include (i) deductions for net income attributable to noncontrolling interests, and (ii) benefits accrued on synthetic GICs accounted for as freestanding derivatives.
Adjusted earnings also excludes the recognition of certain contingent assets and liabilities that could not be recognized at acquisition or adjusted for during the measurement period under GAAP business combination accounting guidance.
The tax impact of the adjustments mentioned above are calculated net of the U.S. or foreign statutory tax rate, which could differ from MetLife's effective tax rate. Additionally, the provision for income tax (expense) benefit also includes the impact related to the timing of certain tax credits, as well as certain tax reforms.
In addition, adjusted earnings available to common shareholders excludes the impact of preferred stock redemption premium which is reported as a reduction to net income (loss) available to MetLife, Inc.’s common shareholders.

Investment portfolio gains (losses) and derivative gains (losses)
These are measures of investment and hedging activity. Investment portfolio gains (losses) principally excludes amounts that are reported within net investment gains (losses) but do not relate to the performance of the investment portfolio, such as gains (losses) on sales and divestitures of businesses, as well as investment portfolio gains (losses) of divested businesses. Derivative gains (losses) principally excludes earned income on derivatives and amortization of premium on derivatives, where such derivatives are either hedges of investments or are used to replicate certain investments, and where such derivatives do not qualify for hedge accounting. This earned income and amortization of premium is reported within adjusted earnings and not within derivative gains (losses).
Return on equity and related measures
•Total MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA: total MetLife, Inc.’s common stockholders’ equity, excluding the net unrealized investment gains (losses), future policy benefits discount rate remeasurement gains (losses), market risk benefits instrument-specific credit risk remeasurement gains (losses) and defined benefit plans adjustment, components of AOCI, net of income tax.
•Total MetLife, Inc.’s common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA): total MetLife, Inc.’s common stockholders’ equity, excluding the net unrealized investment gains (losses), future policy benefits discount rate remeasurement gains (losses), market risk benefits instrument-specific credit risk remeasurement gains (losses), defined benefit plans adjustment, components of AOCI, and total notable items, net of income tax.
•Return on MetLife, Inc.’s common stockholders’ equity: net income (loss) available to MetLife, Inc.’s common shareholders divided by MetLife, Inc.’s average common stockholders’ equity.
•Adjusted return on MetLife, Inc.'s common stockholders' equity: adjusted earnings available to common shareholders divided by MetLife, Inc.'s average common stockholders' equity.
•Adjusted return on MetLife, Inc.'s common stockholders' equity, excluding AOCI other than FCTA: adjusted earnings available to common shareholders divided by MetLife, Inc.'s average common stockholders' equity, excluding AOCI other than FCTA.
•Adjusted return on MetLife, Inc.'s common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA): adjusted earnings available to common shareholders, excluding
Page 12 of 24



total notable items, divided by MetLife, Inc.'s average common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA).
The above measures represent a level of equity consistent with the view that, in the ordinary course of business, MetLife does not plan to sell most investments for the sole purpose of realizing gains or losses.
Expense ratio, direct expense ratio, adjusted expense ratio and related measures
•Expense ratio: other expenses, net of capitalization of DAC, divided by premiums, fees and other revenues.
•Direct expense ratio: adjusted direct expenses, divided by adjusted premiums, fees and other revenues.
•Direct expense ratio, excluding total notable items related to direct expenses and PRT: adjusted direct expenses, excluding total notable items related to direct expenses, divided by adjusted premiums, fees and other revenues, excluding PRT.
•Adjusted expense ratio: adjusted other expenses, net of adjusted capitalization of DAC, divided by adjusted premiums, fees and other revenues.
•Adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT: adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses, divided by adjusted premiums, fees and other revenues, excluding PRT.
Asia General account (GA) assets under management (GA AUM) and related measures
Asia GA AUM is used by MetLife to describe assets in its Asia GA investment portfolio which are actively managed and stated at estimated fair value. Asia GA AUM is comprised of Asia GA total investments, the portion of the Asia GA investment portfolio classified within assets held-for-sale and cash and cash equivalents, excluding policy loans, contractholder-directed equity securities, fair value option securities and certain other invested assets, as substantially all of these assets are not actively managed in MetLife Asia's GA investment portfolio. Mortgage loans (including commercial, agricultural and residential) and real estate equity (including real estate and real estate joint ventures) included in Asia GA AUM (at net asset value, net of deduction for encumbering debt) have been adjusted from carrying value to estimated fair value. At the segment level, intersegment balances (intercompany activity, primarily related to investments in subsidiaries, that eliminate at the MetLife consolidated level) are excluded from Asia GA AUM.
Asia GA AUM (at amortized cost) excludes the following adjustments: (i) unrealized gain (loss) on investments carried at estimated fair value and (ii) adjustments from carrying value to estimated fair value on mortgage loans (including commercial, agricultural and residential) and real estate and real estate joint ventures. Asia GA AUM (at amortized cost) is presented net of related allowance for credit loss.
Statistical sales information:
•U.S.:
◦Group Benefits: calculated using 10% of single premium deposits and 100% of annualized full-year premiums and fees from recurring premium policy sales of all products.
◦Retirement and Income Solutions: calculated using 10% of single premium deposits and 100% of annualized full-year premiums and fees only from recurring premium policy sales of specialized benefit resources and corporate-owned life insurance.

•Latin America, Asia and EMEA: calculated using 10% of single-premium deposits (mainly from retirement products such as variable annuity, fixed annuity and pensions), 20% of single-premium deposits from credit insurance and 100% of annualized full-year premiums and fees from recurring-premium policy sales of all products (mainly from risk and protection products such as individual life, accident & health and group).

Sales statistics do not correspond to revenues under GAAP, but are used as relevant measures of business activity.
Page 13 of 24




The following additional information is relevant to an understanding of MetLife’s performance results and outlook:
•Volume growth, as discussed in the context of business growth, is the period over period percentage change in adjusted earnings available to common shareholders attributable to adjusted premiums, fees and other revenues and assets under management levels, applying a model in which certain margins and factors are held constant. The most significant of such items are underwriting margins, investment margins, changes in equity market performance, expense margins and the impact of changes in foreign currency exchange rates.
•Holding company cash and liquid assets are held by MetLife, Inc. collectively with other MetLife holding companies and include cash and cash equivalents, short term investments and publicly traded securities excluding assets that are pledged or otherwise committed. Assets pledged or otherwise committed include amounts received in connection with securities lending, repurchase agreements, derivatives, regulatory deposits, the collateral financing arrangement, funding agreements and secured borrowings, as well as amounts held in the closed block.
•MetLife uses a measure of free cash flow to facilitate an understanding of its ability to generate cash for reinvestment into its businesses or use in non-mandatory capital actions. MetLife defines free cash flow as the sum of cash available at MetLife’s holding companies from dividends from operating subsidiaries, expenses and other net flows of the holding companies (including capital contributions to subsidiaries), and net contributions from debt to be at or below target leverage ratios. This measure of free cash flow is prior to capital actions, such as common stock dividends and repurchases, debt reduction and mergers and acquisitions. Free cash flow should not be viewed as a substitute for net cash provided by (used in) operating activities calculated in accordance with GAAP. The free cash flow ratio is typically expressed as a percentage of annual adjusted earnings available to common shareholders.
•Notable items reflect the unexpected impact of events that affect MetLife’s results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results. Notable items represent a positive (negative) impact to adjusted earnings available to common shareholders.
•We refer to observable forward yield curves as of a particular date in connection with making our estimates for future results. The observable forward yield curves at a given time are based on implied future interest rates along a range of interest rate durations. This includes the 10-year U.S. Treasury rate which we use as a benchmark rate to describe longer-term interest rates used in our estimates for future results.

Forward-Looking Statements
This news release may contain or incorporate by reference information that includes or is based upon forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give expectations or forecasts of future events and do not relate strictly to historical or current facts. They use words and terms such as “anticipate,” "are confident," “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “if,” “intend,” “likely,” “may,” “plan,” “potential,” “project,” “should,” “will,” “would,” and other words and terms of similar meaning or that are otherwise tied to future periods or future performance, in each case in all derivative forms. They include statements relating to future actions, prospective services or products, future performance or results of current and anticipated services or products, future sales efforts, future expenses, the outcome of contingencies such as legal proceedings, and future trends in operations and financial results.

Many factors determine the results of MetLife, Inc., its subsidiaries and affiliates, and they involve unpredictable risks and uncertainties. Our forward-looking statements depend on our assumptions, our expectations, and our understanding of the economic environment, but they may be inaccurate and may change. MetLife, Inc. does not guarantee any future performance. Our results could differ materially from those MetLife, Inc. expresses or implies in forward-looking statements. The risks, uncertainties and other factors, including those relating to the COVID-19 pandemic, identified in MetLife, Inc.’s filings with the U.S. Securities and Exchange Commission, and others, may cause such differences. These factors include:
Page 14 of 24




(1)economic condition difficulties, including risks relating to public health, interest rates, credit spreads, equity, real estate, obligors and counterparties, government default, currency exchange rates, derivatives, climate change and terrorism and security;
(2)global capital and credit market adversity;
(3)credit facility inaccessibility;
(4)financial strength or credit ratings downgrades;
(5)unavailability, unaffordability, or inadequate reinsurance;
(6)statutory life insurance reserve financing costs or limited market capacity;
(7)legal, regulatory, and supervisory and enforcement policy changes;
(8)changes in tax rates, tax laws or interpretations;
(9)litigation and regulatory investigations;
(10)London Interbank Offered Rate discontinuation and transition to alternative reference rates;
(11)unsuccessful efforts to meet all environmental, social, and governance standards or to enhance our sustainability;
(12)MetLife, Inc.’s inability to pay dividends and repurchase common stock;
(13)MetLife, Inc.’s subsidiaries’ inability to pay dividends to MetLife, Inc.;
(14)investment defaults, downgrades, or volatility;
(15)investment sales or lending difficulties;
(16)collateral or derivative-related payments;
(17)investment valuations, allowances, or impairments changes;
(18)claims or other results that differ from our estimates, assumptions, or models;
(19)global political, legal, or operational risks;
(20)business competition;
(21)technological changes;
(22)catastrophes;
(23)climate changes or responses to it;
(24)deficiencies in our closed block;
(25)goodwill or other asset impairment, or deferred income tax asset allowance;
(26)impairment of VOBA, VODA or VOCRA;
(27)product guarantee volatility, costs, and counterparty risks;
(28)risk management failures;
(29)insufficient protection from operational risks;
(30)failure to protect confidentiality and integrity of data or other cybersecurity or disaster recovery failures;
(31)accounting standards changes;
(32)excessive risk-taking;
(33)marketing and distribution difficulties;
(34)pension and other postretirement benefit assumption changes;
(35)inability to protect our intellectual property or avoid infringement claims;
(36)acquisition, integration, growth, disposition, or reorganization difficulties;
(37)Brighthouse Financial, Inc. separation risks;
(38)MetLife, Inc.’s Board of Directors influence over the outcome of stockholder votes through the voting provisions of the MetLife Policyholder Trust; and
(39)legal- and corporate governance-related effects on business combinations.

MetLife, Inc. does not undertake any obligation to publicly correct or update any forward-looking statements if MetLife, Inc. later becomes aware that such statement is not likely to be achieved. Please consult any further disclosures MetLife, Inc. makes on related subjects in subsequent reports to the U.S. Securities and Exchange Commission.

Page 15 of 24



MetLife, Inc.
GAAP Interim Condensed Consolidated Statements of Operations
(Unaudited)
(In millions)
For the Three Months Ended
March 31,
2023 2022
Revenues
Premiums $ 9,589  $ 10,617 
Universal life and investment-type product policy fees 1,289  1,312 
Net investment income 4,645  4,284 
Other revenues 639  660 
Net investment gains (losses) (684) (517)
Net derivative gains (losses) (90) (951)
Total revenues 15,388  15,405 
Expenses
Policyholder benefits and claims 9,872  11,174 
Policyholder liability remeasurement (gains) losses (9) (41)
Market risk benefit remeasurement (gains) losses 188  (1,440)
Interest credited to policyholder account balances 1,864  626 
Policyholder dividends 159  199 
Amortization of DAC and VOBA 470  475 
Amortization of negative VOBA (7) (8)
Interest expense on debt 255  225 
Other expenses, net of capitalization of DAC 2,339  2,260 
Total expenses 15,131  13,470 
Income (loss) before provision for income tax 257  1,935 
Provision for income tax expense (benefit) 172  296 
Net income (loss) 85  1,639 
Less: Net income (loss) attributable to noncontrolling interests
Net income (loss) attributable to MetLife, Inc. 80  1,634 
Less: Preferred stock dividends 66  63 
Net income (loss) available to MetLife, Inc.'s common shareholders $ 14  $ 1,571 
See footnotes on last page.
Page 16 of 24



MetLife, Inc.
(Unaudited)
(In millions, except per share data)
For the Three Months Ended
March 31,
2023 2022
Reconciliation to Adjusted Earnings Available to Common Shareholders Earnings Per
Weighted Average
Common Share Diluted (1)
Earnings Per
Weighted Average
Common Share Diluted (1)
Net income (loss) available to MetLife, Inc.'s common shareholders $ 14  $ 0.02  $ 1,571  $ 1.89 
Adjustments from net income (loss) available to common shareholders to adjusted earnings available to common shareholders:
Less: Net investment gains (losses) (684) (0.88) (517) (0.62)
Net derivative gains (losses) (90) (0.12) (951) (1.15)
Market risk benefit remeasurement gains (losses) (188) (0.24) 1,440  1.73 
Premiums —  —  41  0.05 
Universal life and investment-type product policy fees —  —  11  0.01 
Net investment income 39  0.05  (708) (0.85)
Other revenues (3) —  50  0.06 
Policyholder benefits and claims and policyholder dividends (70) (0.09) (154) (0.18)
Interest credited to policyholder account balances (322) (0.41) 565  0.69 
Capitalization of DAC —  —  11  0.01 
Amortization of DAC and VOBA —  —  (8) (0.01)
Amortization of negative VOBA —  —  —  — 
Interest expense on debt —  —  —  — 
Other expenses (27) (0.03) (79) (0.10)
Goodwill impairment —  —  —  — 
Provision for income tax (expense) benefit 180  0.23  180  0.22 
Add: Net income (loss) attributable to noncontrolling interests 0.01  0.01 
Preferred stock redemption premium —  —  —  — 
Adjusted earnings available to common shareholders 1,184  1.52  1,695  2.04 
Less: Total notable items (2) —  —  —  — 
Adjusted earnings available to common shareholders, excluding total notable items (2) $ 1,184  $ 1.52  $ 1,695  $ 2.04 
Adjusted earnings available to common shareholders on a constant currency basis $ 1,184  $ 1.52  $ 1,675  $ 2.02 
Adjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis (2) $ 1,184  $ 1.52  $ 1,675  $ 2.02 
Weighted average common shares outstanding - diluted 781.2  830.5 
See footnotes on last page.
Page 17 of 24



MetLife, Inc.
(Unaudited)
(In millions)
 For the Three Months Ended
March 31,
2023 2022
Premiums, Fees and Other Revenues
Premiums, fees and other revenues $ 11,517  $ 12,589 
Less: Adjustments to premiums, fees and other revenues:
Asymmetrical and non-economic accounting —  — 
Other adjustments (3) 47 
Divested businesses —  55 
Adjusted premiums, fees and other revenues $ 11,520  $ 12,487 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 11,520  $ 12,304 
Less: PRT (3) (21) 1,258 
Adjusted premiums, fees and other revenues, excluding PRT, on a constant currency basis $ 11,541  $ 11,046 
Net Investment Income
Net investment income $ 4,645  $ 4,284 
Less: Adjustments to net investment income
Investment hedge adjustments (264) (215)
Unit-linked contract income 303  (498)
Other adjustments —  (6)
Divested business —  11 
Adjusted net investment income $ 4,606  $ 4,992 
Revenues and Expenses
Total revenues $ 15,388  $ 15,405 
Less: Adjustments to total revenues:
Net investment gains (losses) (684) (517)
Net derivative gains (losses) (90) (951)
Investment hedge adjustments (264) (215)
Asymmetrical and non-economic accounting —  — 
Unit-linked contract income 303  (498)
Other adjustments (3) 41 
Divested businesses —  66 
Total adjusted revenues $ 16,126  $ 17,479 
Total expenses $ 15,131  $ 13,470 
Less: Adjustments to total expenses:
Market risk benefit remeasurement (gains) losses 188  (1,440)
Goodwill impairment —  — 
Asymmetrical and non-economic accounting 103  56 
Market volatility (14) 12 
Unit-linked contract costs 303  (505)
Other adjustments 16  47 
Divested businesses 11  55 
Total adjusted expenses $ 14,524  $ 15,245 
See footnotes on last page.
Page 18 of 24



MetLife, Inc.
(Unaudited)
(In millions, except per share and ratio data)
For the Three Months Ended
March 31,
2023 2022
Expense Detail and Ratios
Reconciliation of Capitalization of DAC to Adjusted Capitalization of DAC
Capitalization of DAC $ (718) $ (652)
Less: Divested businesses —  (11)
Adjusted capitalization of DAC $ (718) $ (641)
Reconciliation of Other Expenses to Adjusted Other Expenses
Other expenses $ 3,057  $ 2,912 
Less: Other adjustments 16  47 
Less: Divested businesses 11  32 
Adjusted other expenses $ 3,030  $ 2,833 
Other Detail and Ratios
Other expenses, net of capitalization of DAC $ 2,339  $ 2,260 
Premiums, fees and other revenues $ 11,517  $ 12,589 
Expense ratio 20.3  % 18.0  %
Direct expenses $ 1,387  $ 1,332 
Less: Total notable items related to direct expenses (2) —  — 
Direct expenses, excluding total notable items related to direct expenses (2) $ 1,387  $ 1,332 
Adjusted other expenses $ 3,030  $ 2,833 
Adjusted capitalization of DAC (718) (641)
Adjusted other expenses, net of adjusted capitalization of DAC 2,312  2,192 
Less: Total notable items related to adjusted other expenses (2) —  — 
Adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses (2) $ 2,312  $ 2,192 
Adjusted premiums, fees and other revenues $ 11,520  $ 12,487 
Less: PRT (21) 1,258 
Adjusted premiums, fees and other revenues, excluding PRT $ 11,541  $ 11,229 
Direct expense ratio 12.0  % 10.7  %
Direct expense ratio, excluding total notable items related to direct expenses and PRT (2) 12.0  % 11.9  %
Adjusted expense ratio 20.1  % 17.6  %
Adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT (2) 20.0  % 19.5  %
See footnotes on last page.
Page 19 of 24



MetLife, Inc.
(Unaudited)
(In millions, except per share data)
March 31,
Equity Details 2023 2022
Total MetLife, Inc.'s stockholders' equity $ 32,194  $ 42,432 
Less: Preferred stock 3,818  3,818 
MetLife, Inc.'s common stockholders' equity 28,376  38,614 
Less: Net unrealized investment gains (losses), net of income tax (14,606) 6,083 
Future policy benefits discount rate remeasurement gain (losses), net of income tax 2,748  (9,248)
Market risk benefits instrument-specific credit risk remeasurement gains (losses), net of income tax 186  195 
  Defined benefit plans adjustment, net of income tax (1,356) (1,577)
Total MetLife, Inc.'s common stockholders' equity, excluding AOCI other than FCTA 41,404  43,161 
Less: Accumulated year-to-date total notable items (2) —  — 
Total MetLife, Inc.'s common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA) (2) $ 41,404  $ 43,161 
March 31,
Book Value (4) 2023 2022
Book value per common share $ 36.89  $ 47.39 
Less: Net unrealized investment gains (losses), net of income tax (18.99) 7.47 
Future policy benefits discount rate remeasurement gain (losses), net of income tax 3.57  (11.36)
Market risk benefits instrument-specific credit risk remeasurement gains (losses), net of income tax 0.24  0.24 
   Defined benefit plans adjustment, net of income tax (1.76) (1.93)
Book value per common share, excluding AOCI other than FCTA $ 53.83  $ 52.97 
Common shares outstanding, end of period (5) 769.2  814.8 
For the Three Months Ended
March 31,
Average Common Stockholders' Equity 2023 2022
Average common stockholders' equity $ 27,220  $ 42,272 
Average common stockholders' equity, excluding AOCI other than FCTA $ 41,856  $ 43,210 
Average common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA) (2) $ 41,856  $ 43,210 
For the Three Months Ended
March 31, (6)
Return on Equity 2023 2022
Return on MetLife, Inc.'s:
Common stockholders' equity 0.2  % 14.9  %
Adjusted return on MetLife, Inc.'s:
Common stockholders' equity 17.4  % 16.0  %
Common stockholders' equity, excluding AOCI other than FCTA 11.3  % 15.7  %
Common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA) (2) 11.3  % 15.7  %
See footnotes on last page.

Page 20 of 24



MetLife, Inc.
Adjusted Earnings Available to Common Shareholders
(Unaudited)
(In millions)
For the Three Months Ended
March 31,
2023 2022
U.S. (3):
Adjusted earnings available to common shareholders $ 707  $ 663 
Less: Total notable items (2) —  — 
Adjusted earnings available to common shareholders, excluding total notable items (2) $ 707  $ 663 
Adjusted premiums, fees and other revenues $ 6,697  $ 7,729 
Less: PRT (21) 1,258 
Adjusted premiums, fees and other revenues, excluding PRT $ 6,718  $ 6,471 
Group Benefits (3):
Adjusted earnings available to common shareholders $ 307  $ 117 
Less: Total notable items (2) —  — 
Adjusted earnings available to common shareholders, excluding total notable items (2) $ 307  $ 117 
Adjusted premiums, fees and other revenues $ 6,049  $ 6,004 
Retirement & Income Solutions (3):
Adjusted earnings available to common shareholders $ 400  $ 546 
Less: Total notable items (2) —  — 
Adjusted earnings available to common shareholders, excluding total notable items (2) $ 400  $ 546 
Adjusted premiums, fees and other revenues $ 648  $ 1,725 
Less: PRT (21) 1,258 
Adjusted premiums, fees and other revenues, excluding PRT $ 669  $ 467 
See footnotes on last page.
Page 21 of 24



MetLife, Inc.
Adjusted Earnings Available to Common Shareholders (Continued)
(Unaudited)
(In millions)
For the Three Months Ended
March 31,
2023 2022
Asia:
Adjusted earnings available to common shareholders $ 280  $ 599 
Less: Total notable items (2) —  — 
Adjusted earnings available to common shareholders, excluding total notable items (2) $ 280  $ 599 
Adjusted earnings available to common shareholders on a constant currency basis $ 280  $ 581 
Adjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis (2) $ 280  $ 581 
Adjusted premiums, fees and other revenues $ 1,794  $ 1,976 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 1,794  $ 1,792 
Latin America:
Adjusted earnings available to common shareholders $ 215  $ 135 
Less: Total notable items (2) —  — 
Adjusted earnings available to common shareholders, excluding total notable items (2) $ 215  $ 135 
Adjusted earnings available to common shareholders on a constant currency basis $ 215  $ 142 
Adjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis (2) $ 215  $ 142 
Adjusted premiums, fees and other revenues $ 1,372  $ 1,036 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 1,372  $ 1,087 
EMEA:
Adjusted earnings available to common shareholders $ 60  $ 55 
Less: Total notable items (2) —  — 
Adjusted earnings available to common shareholders, excluding total notable items (2) $ 60  $ 55 
Adjusted earnings available to common shareholders on a constant currency basis $ 60  $ 46 
Adjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis (2) $ 60  $ 46 
Adjusted premiums, fees and other revenues $ 581  $ 601 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 581  $ 551 
MetLife Holdings (3):
Adjusted earnings available to common shareholders $ 158  $ 348 
Less: Total notable items (2) —  — 
Adjusted earnings available to common shareholders, excluding total notable items (2) $ 158  $ 348 
Adjusted premiums, fees and other revenues $ 959  $ 1,048 
Corporate & Other (3):
Adjusted earnings available to common shareholders $ (236) $ (105)
Less: Total notable items (2) —  — 
Adjusted earnings available to common shareholders, excluding total notable items (2) $ (236) $ (105)
Adjusted premiums, fees and other revenues $ 117  $ 97 
See footnotes on last page.





Page 22 of 24







MetLife, Inc.
(Unaudited)
For the Three Months Ended
March 31,
2023 2022
Variable investment income (post-tax, in millions) (7)
U.S.
Group Benefits $ —  $ 12 
Retirement and Income Solutions (3) 277 
Total U.S. (3) 289 
Asia (25) 288 
Latin America (2) 16 
EMEA —  — 
MetLife Holdings 208 
Corporate & Other (7) 135 
Total variable investment income $ (35) $ 936 
See footnotes on last page.

Page 23 of 24



MetLife, Inc.
(Unaudited)
March 31,
2023 2022
Cash & Capital (8), (9), (10) (in billions)
Holding Companies Cash & Liquid Assets
$ 4.2  $ 4.2 
March 31, 2023
Real Estate Equity (11) (in billions)
Unrealized gains on real estate equity $ 6.4 
Footnotes
(1)
Adjusted earnings available to common shareholders, excluding total notable items, per diluted common share is calculated on a standalone basis and may not equal (i) adjusted earnings available to common shareholders per diluted common share, less (ii) total notable items per diluted common share.
(2)
Notable items reflect the unexpected impact of events that affect MetLife’s results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results. Notable items can affect MetLife’s results either positively or negatively.
(3) Results on a constant currency basis are not included as constant currency impact is not significant.
(4) Book values exclude $3,818 million of equity related to preferred stock at both March 31, 2023 and 2022.
(5) There were share repurchases of $0.8 billion for the three months ended March 31, 2023. There were share repurchases of $223 million in April 2023.
(6) Annualized using quarter-to-date results.
(7)
Assumes a 21% tax rate.
(8) The 2022 combined U.S. risk based capital ratio was 367%, which is above MetLife's 360% target on an NAIC basis. This ratio includes MetLife, Inc.'s principal U.S. insurance subsidiaries, excluding American Life Insurance Company. MetLife calculates RBC annually as of December 31 and, accordingly, the calculation does not reflect conditions and factors occurring after the year end.
(9)
The total U.S. statutory adjusted capital is expected to be approximately $17.7 billion at March 31, 2023, down 3% from December 31, 2022. This balance includes MetLife, Inc.'s principal U.S. insurance subsidiaries, excluding American Life Insurance Company.
(10)
As of December 31, 2022, the solvency margin ratio of MetLife's insurance subsidiary in Japan was 701%, which is calculated quarterly and does not reflect conditions and factors occurring after December 31, 2022. The expected Japan solvency margin ratio as of March 31, 2023 is approximately 725%.
(11) Real estate equity fair value of $18.1 billion and carrying value of $11.7 billion.
Page 24 of 24

EX-99.2 3 ex992qfsq123doc-ldti.htm EX-99.2 Document
Exhibit 99.2




 image0a45.jpg
First Quarter
Financial Supplement
March 31, 2023
1


METLIFE
TABLE OF CONTENTS
 
 
 
 
 
1

METLIFE
As used in this QFS, “MetLife," “we” and “our” refer to MetLife, Inc., a Delaware corporation incorporated in 1999, its subsidiaries and affiliates. In this QFS, MetLife presents certain measures of its performance that are not calculated in accordance with GAAP. We believe that these non-GAAP financial measures enhance the understanding for MetLife and its investors of MetLife's performance by highlighting the results of operations and the underlying profitability drivers of our business. See Appendix for definitions of non-GAAP financial measures and other financial disclosures.
GAAP CONSOLIDATED STATEMENTS OF OPERATIONS
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Revenues
Premiums $ 10,617  $ 11,556  $ 17,332  $ 9,005  $ 9,589  $ 10,617  $ 9,589 
Universal life and investment-type product policy fees 1,312  1,372  1,275  1,266  1,289  1,312  1,289 
Net investment income 4,284  3,583  3,585  4,464  4,645  4,284  4,645 
Other revenues 660  615  728  627  639  660  639 
Net investment gains (losses) (517) (682) (411) 350  (684) (517) (684)
Net derivative gains (losses) (951) (970) (226) (104) (90) (951) (90)
Total revenues 15,405  15,474  22,283  15,608  15,388  15,405  15,388 
Expenses
Policyholder benefits and claims 11,174  11,615  17,603  9,115  9,872  11,174  9,872 
Policyholder liability remeasurement (gains) losses (41) (1) 136  20  (9) (41) (9)
Market risk benefit remeasurement (gains) losses (1,440) (757) (965) (512) 188  (1,440) 188 
Interest credited to policyholder account balances 626  527  1,014  1,727  1,864  626  1,864 
Policyholder dividends 199  194  158  155  159  199  159 
Amortization of DAC and VOBA 475  458  441  457  470  475  470 
Amortization of negative VOBA (8) (7) (7) (7) (7) (8) (7)
Interest expense on debt 225  226  239  248  255  225  255 
Other expenses, net of capitalization of DAC 2,260  2,231  2,249  2,379  2,339  2,260  2,339 
Total expenses 13,470  14,486  20,868  13,582  15,131  13,470  15,131 
Income (loss) before provision for income tax 1,935  988  1,415  2,026  257  1,935  257 
Provision for income tax expense (benefit) 296  73  248  445  172  296  172 
Net income (loss) 1,639  915  1,167  1,581  85  1,639  85 
Less: Net income (loss) attributable to noncontrolling interests
Net income (loss) attributable to MetLife, Inc. 1,634  910  1,162  1,578  80  1,634  80 
Less: Preferred stock dividends 63  29  64  29  66  63  66 
Net income (loss) available to MetLife, Inc.'s common shareholders $ 1,571  $ 881  $ 1,098  $ 1,549  $ 14  $ 1,571  $ 14 
Premiums, fees and other revenues $ 12,589  $ 13,543  $ 19,335  $ 10,898  $ 11,517  $ 12,589  $ 11,517 
2

METLIFE
CORPORATE OVERVIEW
For the Three Months Ended
Unaudited (In millions, except per share data) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Net income (loss) available to MetLife, Inc.'s common shareholders $ 1,571  $ 881  $ 1,098  $ 1,549  $ 14 
Adjustments from net income (loss) available to MetLife, Inc.'s common shareholders to adjusted earnings available to common shareholders:
Less: Net investment gains (losses) (517) (682) (411) 350  (684)
Less: Net derivative gains (losses) (951) (970) (226) (104) (90)
Less: Market risk benefit remeasurement gains (losses) 1,440  757  965  512  (188)
Less: Goodwill impairment —  —  —  —  — 
Less: Other adjustments to net income (loss) (1) (271) (396) (435) (317) (383)
Less: Provision for income tax (expense) benefit 180  439  110  (149) 180 
Add: Net income (loss) attributable to noncontrolling interests
Add: Preferred stock redemption premium —  —  —  —  — 
Adjusted earnings available to common shareholders 1,695  1,738  1,100  1,260  1,184 
Less: Total notable items (2) —  77  12  —  — 
Adjusted earnings available to common shareholders, excluding total notable items (2) $ 1,695  $ 1,661  $ 1,088  $ 1,260  $ 1,184 
Net income (loss) available to MetLife, Inc.'s common shareholders per diluted common share $ 1.89  $ 1.08  $ 1.37  $ 1.96  $ 0.02 
Less: Net investment gains (losses) (0.62) (0.84) (0.51) 0.44  (0.88)
Less: Net derivative gains (losses) (1.15) (1.19) (0.28) (0.13) (0.12)
Less: Market risk benefit remeasurement gains (losses) 1.73  0.93  1.21  0.65  (0.24)
Less: Goodwill impairment —  —  —  —  — 
Less: Other adjustments to net income (loss) (0.32) (0.48) (0.55) (0.40) (0.48)
Less: Provision for income tax (expense) benefit 0.22  0.54  0.14  (0.19) 0.23 
Add: Net income (loss) attributable to noncontrolling interests 0.01  0.01  0.01  —  0.01 
Add: Preferred stock redemption premium —  —  —  —  — 
Adjusted earnings available to common shareholders per diluted common share 2.04  2.13  1.37  1.59  1.52 
Less: Total notable items per diluted common share (2) —  0.09  0.01  —  — 
Adjusted earnings available to common shareholders, excluding total notable items, per diluted common share (2), (3) $ 2.04  $ 2.04  $ 1.36  $ 1.59  $ 1.52 
For the Three Months Ended
Unaudited (In millions, except per share data) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Notable items impacting adjusted earnings available to common shareholders (2):
Actuarial assumption review and other insurance adjustments $ —  $ 77  $ 12  $ —  — 
Total notable items  $ —  $ 77  $ 12  $ —  — 
Notable items impacting adjusted earnings available to common shareholders per diluted common share (2):
Actuarial assumption review and other insurance adjustments $ —  $ 0.09  $ 0.01  $ —  — 
Total notable items  $ —  $ 0.09  $ 0.01  $ —  $ — 
For the Three Months Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Weighted average common shares outstanding - diluted 830.5  814.5  800.7  790.2  781.2 
(1)See Appendix for further detail.
(2)These notable items represent a positive (negative) impact to adjusted earnings available to common shareholders and adjusted earnings available to common shareholders per diluted common share. The per share data for each notable item is calculated on a standalone basis and may not sum to total notable items. Notable items reflect the unexpected impact of events that affect MetLife's results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results. See Page A-2 for further detail.
(3)Calculated on a standalone basis and may not equal (i) adjusted earnings available to common shareholders per diluted common share, less (ii) total notable items per diluted common share.

3

METLIFE
CORPORATE OVERVIEW (CONTINUED)
Unaudited March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Book value per common share (1) $ 47.39  $ 37.52  $ 32.48  $ 33.45  $ 36.89 
Book value per common share, excluding AOCI other than FCTA (1) $ 52.97  $ 52.30  $ 52.04  $ 54.30  $ 53.83 
For the Three Months Ended
Unaudited March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Return on MetLife, Inc.'s (2):
Common stockholders' equity 14.9  % 10.3  % 15.8  % 24.0  % 0.2  %
Adjusted return on MetLife, Inc.'s (2):
Common stockholders' equity 16.0  % 20.3  % 15.9  % 19.5  % 17.4  %
Common stockholders' equity, excluding AOCI other than FCTA 15.7  % 16.4  % 10.6  % 12.1  % 11.3  %
Common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA) (3) 15.7  % 15.7  % 10.5  % 12.1  % 11.3  %
For the Three Months Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Common shares outstanding, beginning of period 825.5  814.8  797.6  787.3  779.1 
Share repurchases (13.6) (17.3) (10.3) (8.5) (11.6)
Newly issued shares 2.9  0.1  —  0.3  1.7 
Common shares outstanding, end of period 814.8  797.6  787.3  779.1  769.2 
Weighted average common shares outstanding - basic 823.8  809.7  795.8  784.2  775.4 
Dilutive effect of the exercise or issuance of stock-based awards 6.7  4.8  4.9  6.0  5.8 
Weighted average common shares outstanding - diluted 830.5  814.5  800.7  790.2  781.2 
MetLife Policyholder Trust Shares 127.8  126.2  125.1  123.6  122.1 
(1) Calculated using common shares outstanding, end of period.
(2) Annualized using quarter-to-date results. See Page A-4 for further detail.
(3)Notable items reflect the unexpected impact of events that affect MetLife’s results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results. Notable items can affect MetLife’s results either positively or negatively. See Page A-2 for further detail.

4

METLIFE
KEY ADJUSTED EARNINGS STATEMENT LINE ITEMS
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Total revenues $ 15,405  $ 15,474  $ 22,283  $ 15,608  $ 15,388  $ 15,405  $ 15,388 
Less: Adjustments to total revenues:
Net investment gains (losses) (517) (682) (411) 350  (684) (517) (684)
Net derivative gains (losses) (951) (970) (226) (104) (90) (951) (90)
Investment hedge adjustments (215) (232) (252) (277) (264) (215) (264)
Asymmetrical and non-economic accounting —  —  —  —  —  —  — 
Unit-linked contract income (498) (688) (321) 209  303  (498) 303 
Other adjustments 41  47  35  27  (3) 41  (3)
Divested businesses
66  —  —  —  —  66  — 
Total adjusted revenues $ 17,479  $ 17,999  $ 23,458  $ 15,403  $ 16,126  $ 17,479  $ 16,126 
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Net investment income $ 4,284  $ 3,583  $ 3,585  $ 4,464  $ 4,645  $ 4,284  $ 4,645 
Less: Adjustments to net investment income:
Investment hedge adjustments (215) (232) (252) (277) (264) (215) (264)
Unit-linked contract income (498) (688) (321) 209  303  (498) 303 
Other adjustments (6) (1) (5) —  (6) — 
Divested businesses 11  —  —  —  —  11  — 
Adjusted net investment income $ 4,992  $ 4,504  $ 4,163  $ 4,530  $ 4,606  $ 4,992  $ 4,606 
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Variable investment income (Included in net investment income above) $ 1,185  $ 389  $ (53) $ 24  $ (44) $ 1,185  $ (44)
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Premiums, fees and other revenues $ 12,589  $ 13,543  $ 19,335  $ 10,898  $ 11,517  $ 12,589  $ 11,517 
Less: Adjustments to premiums, fees and other revenues:
Asymmetrical and non-economic accounting —  —  —  —  —  —  — 
Other adjustments 47  48  40  25  (3) 47  (3)
Divested businesses
55  —  —  —  —  55  — 
Adjusted premiums, fees and other revenues $ 12,487  $ 13,495  $ 19,295  $ 10,873  $ 11,520  $ 12,487  $ 11,520 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 12,304  $ 13,479  $ 19,447  $ 11,042  $ 11,520 
5

METLIFE
KEY ADJUSTED EARNINGS STATEMENT LINE ITEMS (CONTINUED)
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Total expenses $ 13,470  $ 14,486  $ 20,868  $ 13,582  $ 15,131  $ 13,470  $ 15,131 
Less: Adjustments to total expenses:
Market risk benefit remeasurement (gains) losses (1,440) (757) (965) (512) 188  (1,440) 188 
Goodwill impairment —  —  —  —  —  —  — 
Asymmetrical and non-economic accounting 56  184  205  143  103  56  103 
Market volatility 12  (34) (66) (105) (14) 12  (14)
Unit-linked contract costs (505) (695) (302) 180  303  (505) 303 
Other adjustments 47  60  47  37  16  47  16 
Divested businesses
55  13  21  11  55  11 
Total adjusted expenses $ 15,245  $ 15,720  $ 21,936  $ 13,818  $ 14,524  $ 15,245  $ 14,524 
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Capitalization of DAC $ (652) $ (637) $ (626) $ (699) $ (718) $ (652) $ (718)
Less: Divested businesses (11) —  —  —  —  (11) — 
Adjusted capitalization of DAC $ (641) $ (637) $ (626) $ (699) $ (718) $ (641) $ (718)
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Other expenses $ 2,912  $ 2,868  $ 2,875  $ 3,078  $ 3,057  $ 2,912  $ 3,057 
Less: Adjustments to other expenses:
Other adjustments 47  60  47  37  16  47  16 
Divested businesses 32  13  21  11  32  11 
Adjusted other expenses $ 2,833  $ 2,800  $ 2,815  $ 3,020  $ 3,030  $ 2,833  $ 3,030 
Adjusted other expenses on a constant currency basis $ 2,742  $ 2,783  $ 2,871  $ 3,095  $ 3,030 
6

METLIFE
EXPENSE DETAIL AND RATIOS
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions, except ratio data) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Other expenses, net of capitalization of DAC $ 2,260  $ 2,231  $ 2,249  $ 2,379  $ 2,339  $ 2,260  $ 2,339 
Premiums, fees and other revenues $ 12,589  $ 13,543  $ 19,335  $ 10,898  $ 11,517  $ 12,589  $ 11,517 
Expense ratio 18.0  % 16.5  % 11.6  % 21.8  % 20.3  % 18.0  % 20.3  %
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Adjusted other expenses by major category
Direct expenses $ 1,332  $ 1,335  $ 1,342  $ 1,481  $ 1,387  $ 1,332  $ 1,387 
Pension, postretirement and postemployment benefit costs 25  24  24  25  59  25  59 
Premium taxes, other taxes, and licenses & fees 151  137  172  146  161  151  161 
Commissions and other variable expenses 1,325  1,304  1,277  1,368  1,423  1,325  1,423 
Adjusted other expenses
2,833  2,800  2,815  3,020  3,030  2,833  3,030 
Adjusted capitalization of DAC (641) (637) (626) (699) (718) (641) (718)
Adjusted other expenses, net of adjusted capitalization of DAC
2,192  2,163  2,189  2,321  2,312  2,192  2,312 
Less: Total notable items related to adjusted other expenses (1) —  —  —  —  —  —  — 
Adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses (1)
$ 2,192  $ 2,163  $ 2,189  $ 2,321  $ 2,312  $ 2,192  $ 2,312 
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions, except ratio data) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Employee related costs $ 899  $ 866  $ 875  $ 864  $ 929  $ 899  $ 929 
Third party staffing costs 375  371  349  433  331  375  331 
General and administrative expenses 58  98  118  184  127  58  127 
Direct expenses 1,332  1,335  1,342  1,481  1,387  1,332  1,387 
Less: Total notable items related to direct expenses (1) —  —  —  —  —  —  — 
Direct expenses, excluding total notable items related to direct expenses (1) $ 1,332  $ 1,335  $ 1,342  $ 1,481  $ 1,387  $ 1,332  $ 1,387 
Adjusted other expenses, net of adjusted capitalization of DAC
$ 2,192  $ 2,163  $ 2,189  $ 2,321  $ 2,312  $ 2,192  $ 2,312 
Less: Total notable items related to adjusted other expenses (1) —  —  —  —  —  —  — 
Adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses (1)
$ 2,192  $ 2,163  $ 2,189  $ 2,321  $ 2,312  $ 2,192  $ 2,312 
Adjusted premiums, fees and other revenues $ 12,487  $ 13,495  $ 19,295  $ 10,873  $ 11,520  $ 12,487  $ 11,520 
Less: PRT 1,258  2,564  8,466  (69) (21) 1,258  (21)
Adjusted premiums, fees and other revenues, excluding PRT $ 11,229  $ 10,931  $ 10,829  $ 10,942  $ 11,541  $ 11,229  $ 11,541 
Direct expense ratio 10.7  % 9.9  % 7.0  % 13.6  % 12.0  % 10.7  % 12.0  %
Direct expense ratio, excluding total notable items related to direct expenses and PRT (1) 11.9  % 12.2  % 12.4  % 13.5  % 12.0  % 11.9  % 12.0  %
Adjusted expense ratio 17.6  % 16.0  % 11.3  % 21.3  % 20.1  % 17.6  % 20.1  %
Adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT (1) 19.5  % 19.8  % 20.2  % 21.2  % 20.0  % 19.5  % 20.0  %
(1)Notable items reflect the unexpected impact of events that affect MetLife’s results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results. Notable items can affect MetLife’s results either positively or negatively. See Page A-2 for further detail.

7

METLIFE
GAAP CONSOLIDATED BALANCE SHEETS
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
ASSETS
Investments:
Fixed maturity securities available-for-sale, at estimated fair value $ 320,079  $ 284,178  $ 270,765  $ 276,780  $ 283,854 
Equity securities, at estimated fair value 988  1,085  973  1,684  1,695 
Contractholder-directed equity securities and fair value option securities, at estimated fair value 11,418  9,875  8,954  9,668  10,063 
Mortgage loans 79,968  82,055  82,437  83,763  85,572 
Policy loans 9,036  8,876  8,783  8,874  8,863 
Real estate and real estate joint ventures 12,379  12,376  12,532  13,137  13,155 
Other limited partnership interests 14,570  14,636  14,387  14,414  14,437 
Short-term investments, principally at estimated fair value 3,146  3,043  5,266  4,935  4,184 
Other invested assets 18,696  19,901  22,299  20,038  19,479 
Total investments 470,280  436,025  426,396  433,293  441,302 
Cash and cash equivalents, principally at estimated fair value 23,488  20,548  22,200  20,195  18,456 
Accrued investment income 3,251  3,154  3,355  3,446  3,554 
Premiums, reinsurance and other receivables 17,983  17,713  17,550  17,364  18,692 
Market risk benefits 18  25  253  280  227 
Deferred policy acquisition costs and value of business acquired 19,747  18,946  18,545  19,653  19,976 
Current income tax recoverable 39  274  194  42  — 
Deferred income tax assets 1,241  1,949  2,161  2,439  2,257 
Goodwill 9,510  9,151  9,005  9,297  9,379 
Assets held-for-sale 4,581  —  —  —  — 
Other assets 11,531  11,280  10,992  11,025  12,006 
Separate account assets 165,056  143,829  135,771  146,038  148,417 
Total assets $ 726,725  $ 662,894  $ 646,422  $ 663,072  $ 674,266 
LIABILITIES AND EQUITY
Liabilities
Future policy benefits $ 199,115  $ 184,916  $ 180,812  $ 187,222  $ 191,741 
Policyholder account balances 214,237  207,921  205,279  210,597  212,569 
Market risk benefits 5,433  4,704  4,039  3,763  3,869 
Other policy-related balances 19,405  18,652  18,509  18,424  19,598 
Policyholder dividends payable 450  457  429  387  356 
Payables for collateral under securities loaned and other transactions 30,481  23,819  24,890  20,937  19,863 
Short-term debt 323  196  183  175  168 
Long-term debt 13,848  13,677  14,520  14,647  14,622 
Collateral financing arrangement 754  741  729  716  704 
Junior subordinated debt securities 3,156  3,157  3,158  3,158  3,159 
Current income tax payable —  —  —  —  554 
Deferred income tax liability 3,622  1,828  991  950  1,111 
Liabilities held-for-sale 4,280  —  —  —  — 
Other liabilities 23,862  24,988  27,472  25,933  25,112 
Separate account liabilities 165,056  143,829  135,771  146,038  148,417 
Total liabilities 684,022  628,885  616,782  632,947  641,843 
Equity
Preferred stock, at par value —  —  —  —  — 
Common stock, at par value 12  12  12  12  12 
Additional paid-in capital 33,531  33,548  33,589  33,616  33,617 
Retained earnings 38,005  38,478  39,176  40,332  39,957 
Treasury stock, at cost (19,072) (20,188) (20,862) (21,458) (22,245)
Accumulated other comprehensive income (loss) (10,044) (18,106) (22,526) (22,621) (19,147)
Total MetLife, Inc.'s stockholders' equity 42,432  33,744  29,389  29,881  32,194 
Noncontrolling interests 271  265  251  244  229 
Total equity 42,703  34,009  29,640  30,125  32,423 
Total liabilities and equity $ 726,725  $ 662,894  $ 646,422  $ 663,072  $ 674,266 
8

METLIFE
SUMMARY OF ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS 
   For the Three Months Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Adjusted earnings before provision for income tax
U.S.
GROUP BENEFITS $ 149  $ 515  $ 530  $ 495  $ 391 
RETIREMENT AND INCOME SOLUTIONS 688  473  420  477  505 
TOTAL U.S. $ 837  $ 988  $ 950  $ 972  $ 896 
ASIA 837  684  385  369  405 
LATIN AMERICA 183  330  203  233  303 
EMEA 72  88  90  72  76 
METLIFE HOLDINGS 435  479  143  228  195 
CORPORATE & OTHER (130) (290) (249) (289) (273)
Total adjusted earnings before provision for income tax
$ 2,234  $ 2,279  $ 1,522  $ 1,585  $ 1,602 
Provision for income tax expense (benefit)
U.S.
GROUP BENEFITS $ 32  $ 109  $ 113  $ 103  $ 84 
RETIREMENT AND INCOME SOLUTIONS 142  99  86  96  105 
TOTAL U.S. $ 174  $ 208  $ 199  $ 199  $ 189 
ASIA 238  198  118  104  125 
LATIN AMERICA 48  79  44  49  88 
EMEA 17  22  26  16 
METLIFE HOLDINGS 87  97  26  44  37 
CORPORATE & OTHER (88) (92) (55) (108) (103)
Total provision for income tax expense (benefit)
$ 476  $ 512  $ 358  $ 296  $ 352 
Adjusted earnings available to common shareholders
U.S.
GROUP BENEFITS $ 117  $ 406  $ 417  $ 392  $ 307 
RETIREMENT AND INCOME SOLUTIONS 546  374  334  381  400 
TOTAL U.S. $ 663  $ 780  $ 751  $ 773  $ 707 
ASIA 599  486  267  265  280 
LATIN AMERICA 135  251  159  184  215 
EMEA 55  66  64  64  60 
METLIFE HOLDINGS 348  382  117  184  158 
CORPORATE & OTHER (1) (105) (227) (258) (210) (236)
Total adjusted earnings available to common shareholders (1) $ 1,695  $ 1,738  $ 1,100  $ 1,260  $ 1,184 
(1)Includes impact of preferred stock dividends of $63 million, $29 million, $64 million, $29 million and $66 million for the three months ended March 31, 2022, June 30, 2022, September 30, 2022, December 31, 2022 and March 31, 2023, respectively.
9

U.S.
STATEMENTS OF ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS
   For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Adjusted revenues
Premiums $ 7,005  $ 8,094  $ 13,954  $ 5,617  $ 5,952  $ 7,005  $ 5,952 
Universal life and investment-type product policy fees 298  283  286  291  297  298  297 
Net investment income 1,874  1,710  1,716  2,040  2,124  1,874  2,124 
Other revenues 426  404  514  408  448  426  448 
Total adjusted revenues 9,603  10,491  16,470  8,356  8,821  9,603  8,821 
Adjusted expenses
Policyholder benefits and claims and policyholder dividends 7,417  8,115  13,978  5,729  6,219  7,417  6,219 
Policyholder liability remeasurement (gains) losses (23) (7) (8) (33) (23) (33)
Interest credited to policyholder account balances 406  453  548  650  692  406  692 
Capitalization of DAC (32) (23) (38) (38) (51) (32) (51)
Amortization of DAC and VOBA 17  15  17  17  17  17  17 
Amortization of negative VOBA —  —  —  —  —  —  — 
Interest expense on debt
Other expenses 979  949  1,003  1,031  1,078  979  1,078 
Total adjusted expenses 8,766  9,503  15,520  7,384  7,925  8,766  7,925 
Adjusted earnings before provision for income tax 837  988  950  972  896  837  896 
Provision for income tax expense (benefit) 174  208  199  199  189  174  189 
Adjusted earnings 663  780  751  773  707  663  707 
Preferred stock dividends —  —  —  —  —  —  — 
Adjusted earnings available to common shareholders $ 663  $ 780  $ 751  $ 773  $ 707  $ 663  $ 707 
Adjusted premiums, fees and other revenues $ 7,729  $ 8,781  $ 14,754  $ 6,316  $ 6,697  $ 7,729  $ 6,697 
Less: PRT
1,258  2,564  8,466  (69) (21) 1,258  (21)
Adjusted premiums, fees and other revenues, excluding PRT $ 6,471  $ 6,217  $ 6,288  $ 6,385  $ 6,718  $ 6,471  $ 6,718 
10

U.S.
GROUP BENEFITS
STATEMENTS OF ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Adjusted revenues
Premiums $ 5,433  $ 5,210  $ 5,161  $ 5,247  $ 5,451  $ 5,433  $ 5,451 
Universal life and investment-type product policy fees 216  210  215  214  218  216  218 
Net investment income 280  278  279  299  310  280  310 
Other revenues 355  336  331  338  380  355  380 
Total adjusted revenues 6,284  6,034  5,986  6,098  6,359  6,284  6,359 
Adjusted expenses
Policyholder benefits and claims and policyholder dividends 5,253  4,640  4,538  4,645  4,994  5,253  4,994 
Policyholder liability remeasurement (gains) losses (1) (4) (1) (4)
Interest credited to policyholder account balances 31  32  34  46  46  31  46 
Capitalization of DAC (4) (6) (4) (4) (6) (4) (6)
Amortization of DAC and VOBA
Amortization of negative VOBA —  —  —  —  —  —  — 
Interest expense on debt —  —  —  —  —  — 
Other expenses 850  844  876  908  932  850  932 
Total adjusted expenses 6,135  5,519  5,456  5,603  5,968  6,135  5,968 
Adjusted earnings before provision for income tax 149  515  530  495  391  149  391 
Provision for income tax expense (benefit) 32  109  113  103  84  32  84 
Adjusted earnings 117  406  417  392  307  117  307 
Preferred stock dividends —  —  —  —  —  —  — 
Adjusted earnings available to common shareholders $ 117  $ 406  $ 417  $ 392  $ 307  $ 117  $ 307 
Adjusted premiums, fees and other revenues $ 6,004  $ 5,756  $ 5,707  $ 5,799  $ 6,049  $ 6,004  $ 6,049 
11

U.S.
RETIREMENT AND INCOME SOLUTIONS
STATEMENTS OF ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Adjusted revenues
Premiums $ 1,572  $ 2,884  $ 8,793  $ 370  $ 501  $ 1,572  $ 501 
Universal life and investment-type product policy fees 82  73  71  77  79  82  79 
Net investment income 1,594  1,432  1,437  1,741  1,814  1,594  1,814 
Other revenues 71  68  183  70  68  71  68 
Total adjusted revenues 3,319  4,457  10,484  2,258  2,462  3,319  2,462 
Adjusted expenses
Policyholder benefits and claims and policyholder dividends 2,164  3,475  9,440  1,084  1,225  2,164  1,225 
Policyholder liability remeasurement (gains) losses (22) (9) (10) (29) (22) (29)
Interest credited to policyholder account balances 375  421  514  604  646  375  646 
Capitalization of DAC (28) (17) (34) (34) (45) (28) (45)
Amortization of DAC and VOBA 11  10  11  11  11  11 
Amortization of negative VOBA —  —  —  —  —  —  — 
Interest expense on debt
Other expenses 129  105  127  123  146  129  146 
Total adjusted expenses 2,631  3,984  10,064  1,781  1,957  2,631  1,957 
Adjusted earnings before provision for income tax 688  473  420  477  505  688  505 
Provision for income tax expense (benefit) 142  99  86  96  105  142  105 
Adjusted earnings 546  374  334  381  400  546  400 
Preferred stock dividends —  —  —  —  —  —  — 
Adjusted earnings available to common shareholders $ 546  $ 374  $ 334  $ 381  $ 400  $ 546  $ 400 
Adjusted premiums, fees and other revenues $ 1,725  $ 3,025  $ 9,047  $ 517  $ 648  $ 1,725  $ 648 
Less: PRT
1,258  2,564  8,466  (69) (21) 1,258  (21)
Adjusted premiums, fees and other revenues, excluding PRT $ 467  $ 461  $ 581  $ 586  $ 669  $ 467  $ 669 
12

U.S.
GROUP BENEFITS
OTHER EXPENSES BY MAJOR CATEGORY
   For the Three Months Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Direct and allocated expenses $ 438  $ 436  $ 444  $ 475  $ 474 
Pension, postretirement and postemployment benefit costs (1) 13 
Premium taxes, other taxes, and licenses & fees 77  73  88  80  80 
Commissions and other variable expenses 334  334  342  354  365 
Adjusted other expenses $ 850  $ 844  $ 876  $ 908  $ 932 
OTHER STATISTICAL INFORMATION (1)
   For the Three Months Ended
Unaudited (In millions, except ratios) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Group Life (2)
Adjusted premiums, fees and other revenues $ 2,180  $ 2,126  $ 2,125  $ 2,131  $ 2,232 
Mortality ratio 103.3  % 85.4  % 85.7  % 87.3  % 90.5  %
Group Non-Medical Health (3)
Adjusted premiums, fees and other revenues $ 2,519  $ 2,481  $ 2,475  $ 2,533  $ 2,601 
Interest adjusted benefit ratio (4) 72.6  % 73.1  % 70.1  % 70.1  % 72.9  %
(1) Results are derived from insurance and non-administrative services-only contracts.
(2) Excludes certain experience-rated contracts and includes accidental death and dismemberment.
(3) Includes dental, group and individual disability, accident & health, critical illness, vision and other health.
(4) Reflects actual claims experience and excludes the impact of interest credited on future policyholder benefits. The product within Group Non-Medical Health with interest credited on future policyholder benefits is disability.
13

U.S.
RETIREMENT AND INCOME SOLUTIONS
 
FUTURE POLICY BENEFITS (1)
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Balance, end of period (at balance sheet discount rate) (2) $ 62,407  $ 58,840  $ 61,264  $ 62,737  $ 63,671 
Less: Accumulated other comprehensive (income) loss 6,107  720  (4,531) (2,856) (1,302)
Balance, end of period (at original discount rate) $ 56,300  $ 58,120  $ 65,795  $ 65,593  $ 64,973 
POLICYHOLDER ACCOUNT BALANCES
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Balance, end of period $ 81,177  $ 79,821  $ 79,311  $ 80,066  $ 79,973 
SEPARATE ACCOUNT LIABILITIES
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Balance, end of period $ 69,123  $ 61,622  $ 58,838  $ 60,040  $ 57,990 
SYNTHETIC GICS (3), (4)
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Balance, end of period $ 43,485  $ 44,841  $ 45,066  $ 46,316  $ 47,850 
LONGEVITY REINSURANCE (5)
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Balance, end of period $ 14,898  $ 14,753  $ 13,427  $ 16,602  $ 17,085 
(1)Includes $3,206 million, $3,291 million, $3,394 million, $3,392 million and $3,449 million of DPL at March 31, 2022, June 30, 2022, September 30, 2022, December 31, 2022 and March 31, 2023, respectively.
(2)Represents the current discount rate at the respective balance sheet date.
(3)A synthetic GIC is a contract that simulates the performance of a traditional GIC through the use of financial instruments and is reported as a derivative. A key difference between a synthetic GIC and a traditional GIC is that the contractholder owns the assets underlying the synthetic GIC. The assets and corresponding contractholder account balance are not on MetLife, Inc.'s consolidated balance sheet, as they are for a traditional GIC. The contractholder account balance is reported at contract value in the table above.
(4)Includes $1,884 million, $0, $0, $147 million and $2,262 million of transfers from separate account GICs to synthetic GICs at March 31, 2022, June 30, 2022, September 30, 2022, December 31, 2022 and March 31, 2023, respectively. These transfers are reported as surrenders and withdrawals on the separate account liabilities table and premiums and deposits on the synthetic GICs table.
(5)The contract value presented represents notional amounts based on the present value of fixed annuity premiums related to longevity reinsurance contracts associated with the United Kingdom pension risk transfer market.
14

U.S.
RETIREMENT AND INCOME SOLUTIONS
OTHER EXPENSES BY MAJOR CATEGORY
For the Three Months Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Direct and allocated expenses $ 65  $ 61  $ 64  $ 70  $ 71 
Pension, postretirement and postemployment benefit costs —  —  — 
Premium taxes, other taxes, and licenses & fees 22  10 
Commissions and other variable expenses 59  39  41  43  63 
Adjusted other expenses $ 129  $ 105  $ 127  $ 123  $ 146 
SPREAD
For the Three Months Ended
Unaudited March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Investment income yield excluding variable investment income yield 3.63  % 3.88  % 4.20  % 4.69  % 4.98  %
Variable investment income yield 26.95  % 7.03  % (3.24) % 0.50  % (0.27) %
Total investment income yield 4.52  % 4.01  % 3.90  % 4.53  % 4.78  %
Average crediting rate 2.84  % 2.96  % 3.29  % 3.65  % 3.82  %
Amortization of DPL and losses at inception (1) (0.21) % (0.21) % (0.21) % (0.20) % (0.21) %
Total average crediting rate 2.63  % 2.75  % 3.08  % 3.45  % 3.61  %
Annualized general account spread 1.89  % 1.26  % 0.82  % 1.08  % 1.17  %
Annualized general account spread excluding variable investment income yield 1.00  % 1.13  % 1.12  % 1.24  % 1.37  %
(1) Includes the amortization of DPL of (0.21)%, (0.21)%, (0.22)%, (0.20)% and (0.22)% for the three months ended March 31, 2022, June 30, 2022, September 30, 2022, December 31, 2022 and March 31, 2023, respectively.
15

ASIA
STATEMENTS OF ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS 
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Adjusted revenues
Premiums $ 1,552  $ 1,393  $ 1,346  $ 1,272  $ 1,377  $ 1,552  $ 1,377 
Universal life and investment-type product policy fees 403  420  438  432  397  403  397 
Net investment income 1,242  1,012  827  828  881  1,242  881 
Other revenues 21  24  21  24  20  21  20 
Total adjusted revenues 3,218  2,849  2,632  2,556  2,675  3,218  2,675 
Adjusted expenses
Policyholder benefits and claims and policyholder dividends 1,271  1,123  1,119  1,051  1,130  1,271  1,130 
Policyholder liability remeasurement (gains) losses (24) (10) 61  42  11  (24) 11 
Interest credited to policyholder account balances 498  493  497  515  536  498  536 
Capitalization of DAC (388) (381) (351) (410) (401) (388) (401)
Amortization of DAC and VOBA 194  182  178  191  193  194  193 
Amortization of negative VOBA (7) (5) (6) (6) (6) (7) (6)
Interest expense on debt —  —  —  —  —  —  — 
Other expenses 837  763  749  804  807  837  807 
Total adjusted expenses 2,381  2,165  2,247  2,187  2,270  2,381  2,270 
Adjusted earnings before provision for income tax 837  684  385  369  405  837  405 
Provision for income tax expense (benefit) 238  198  118  104  125  238  125 
Adjusted earnings 599  486  267  265  280  599  280 
Preferred stock dividends —  —  —  —  —  —  — 
Adjusted earnings available to common shareholders $ 599  $ 486  $ 267  $ 265  $ 280  $ 599  $ 280 
Adjusted premiums, fees and other revenues $ 1,976  $ 1,837  $ 1,805  $ 1,728  $ 1,794  $ 1,976  $ 1,794 
16

ASIA
ADJUSTED PREMIUMS, FEES AND OTHER REVENUES
For the Three Months Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Adjusted premiums, fees and other revenues $ 1,976  $ 1,837  $ 1,805  $ 1,728  $ 1,794 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 1,792  $ 1,795  $ 1,856  $ 1,814  $ 1,794 
Add: Operating joint ventures, on a constant currency basis (1) 372  300  390  379  499 
Adjusted premiums, fees and other revenues, including operating joint ventures, on a constant currency basis $ 2,164  $ 2,095  $ 2,246  $ 2,193  $ 2,293 
OTHER EXPENSES BY MAJOR CATEGORY
For the Three Months Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Direct and allocated expenses $ 326  $ 291  $ 285  $ 300  $ 303 
Pension, postretirement and postemployment benefit costs 20  19  17  23  17 
Premium taxes, other taxes, and licenses & fees 39  31  36  37  33 
Commissions and other variable expenses 452  422  411  444  454 
Adjusted other expenses $ 837  $ 763  $ 749  $ 804  $ 807 
Adjusted other expenses, net of adjusted capitalization of DAC $ 449  $ 382  $ 398  $ 394  $ 406 
Adjusted other expenses on a constant currency basis $ 753  $ 746  $ 775  $ 848  $ 807 
Add: Operating joint ventures, on a constant currency basis (2) 110  102  111  111  129 
Adjusted other expenses, including operating joint ventures, on a constant currency basis $ 863  $ 848  $ 886  $ 959  $ 936 
Adjusted other expenses, including operating joint ventures, net of adjusted capitalization of DAC, on a constant currency basis
$ 487  $ 456  $ 500  $ 507  $ 501 
SALES ON A CONSTANT CURRENCY BASIS
For the Three Months Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Japan:
Life $ 182  $ 107  $ 102  $ 103  $ 84 
Accident & Health 76  74  69  64  68 
Annuities 97  129  202  267  264 
Other
Total Japan 357  312  376  436  418 
Other Asia 195  160  215  195  235 
   Total sales $ 552  $ 472  $ 591  $ 631  $ 653 
OTHER STATISTICAL INFORMATION
For the Three Months Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Adjusted earnings available to common shareholders $ 599  $ 486  $ 267  $ 265  $ 280 
Adjusted earnings available to common shareholders, on a constant currency basis $ 581  $ 478  $ 267  $ 270  $ 280 
(1)Includes MetLife, Inc.'s share of adjusted premiums, fees and other revenues for operating joint ventures of: (i) China, (ii) India, (iii) Malaysia and (iv) Vietnam, on the basis of proportional consolidation and MetLife's percentage ownership. These operating joint ventures are accounted for using the equity method of accounting under GAAP.
(2)Includes MetLife, Inc.'s share of adjusted other expenses for operating joint ventures of: (i) China, (ii) India, (iii) Malaysia and (iv) Vietnam, on the basis of proportional consolidation and MetLife's percentage ownership. These operating joint ventures are accounted for using the equity method of accounting under GAAP.

17

ASIA
ASIA GENERAL ACCOUNT ASSETS UNDER MANAGEMENT AND RELATED MEASURES
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
GA AUM $ 131,989  $ 117,597  $ 109,930  $ 116,289  $ 121,072 
GA AUM (at amortized cost) $ 129,935  $ 122,257  $ 119,302  $ 126,335  $ 127,120 
GA AUM (at amortized cost), on a constant currency basis $ 123,037  $ 122,692  $ 124,115  $ 125,516  $ 127,120 
  Add: Operating joint ventures, on a constant currency basis (1) 6,997  7,212  7,411  7,774  8,201 
GA AUM (at amortized cost), including operating joint ventures, on a constant currency basis $ 130,034  $ 129,904  $ 131,526  $ 133,290  $ 135,321 
(1)Includes MetLife, Inc.'s share of GA AUM for operating joint ventures of: (i) China, (ii) India, (iii) Malaysia and (iv) Vietnam, on the basis of proportional consolidation and MetLife's percentage ownership. These operating joint ventures are accounted for using the equity method of accounting under GAAP.
18

LATIN AMERICA
STATEMENTS OF ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS
 
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Adjusted revenues
Premiums $ 738  $ 822  $ 822  $ 842  $ 1,025  $ 738  $ 1,025 
Universal life and investment-type product policy fees 289  294  293  299  335  289  335 
Net investment income 322  459  399  413  379  322  379 
Other revenues 10  10  10  12  12 
Total adjusted revenues 1,358  1,585  1,524  1,564  1,751  1,358  1,751 
Adjusted expenses
Policyholder benefits and claims and policyholder dividends 780  812  872  856  966  780  966 
Policyholder liability remeasurement (gains) losses (14) (16) (4) (14) (4)
Interest credited to policyholder account balances 68  84  89  94  99  68  99 
Capitalization of DAC (111) (116) (130) (137) (151) (111) (151)
Amortization of DAC and VOBA 100  101  104  105  106  100  106 
Amortization of negative VOBA —  —  —  —  —  —  — 
Interest expense on debt
Other expenses 349  364  380  427  430  349  430 
Total adjusted expenses 1,175  1,255  1,321  1,331  1,448  1,175  1,448 
Adjusted earnings before provision for income tax 183  330  203  233  303  183  303 
Provision for income tax expense (benefit) 48  79  44  49  88  48  88 
Adjusted earnings 135  251  159  184  215  135  215 
Preferred stock dividends —  —  —  —  —  —  — 
Adjusted earnings available to common shareholders $ 135  $ 251  $ 159  $ 184  $ 215  $ 135  $ 215 
Adjusted premiums, fees and other revenues $ 1,036  $ 1,126  $ 1,125  $ 1,151  $ 1,372  $ 1,036  $ 1,372 
19

LATIN AMERICA
OTHER EXPENSES BY MAJOR CATEGORY
For the Three Months Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Direct and allocated expenses $ 121  $ 116  $ 116  $ 140  $ 133 
Pension, postretirement and postemployment benefit costs
Premium taxes, other taxes, and licenses & fees 12  11  12  13  21 
Commissions and other variable expenses 215  236  251  273  275 
Adjusted other expenses $ 349  $ 364  $ 380  $ 427  $ 430 
Adjusted other expenses, net of adjusted capitalization of DAC $ 238  $ 248  $ 250  $ 290  $ 279 
Adjusted other expenses on a constant currency basis $ 362  $ 373  $ 407  $ 452  $ 430 
Adjusted other expenses, net of adjusted capitalization of DAC, on a constant currency basis $ 251  $ 253  $ 267  $ 307  $ 279 
SALES ON A CONSTANT CURRENCY BASIS
For the Three Months Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Mexico $ 167  $ 136  $ 139  $ 138  203 
Chile 72  86  91  95  101 
All other 54  64  80  82  94 
Total sales $ 293  $ 286  $ 310  $ 315  $ 398 
OTHER STATISTICAL INFORMATION
For the Three Months Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Adjusted premiums, fees and other revenues $ 1,036  $ 1,126  $ 1,125  $ 1,151  $ 1,372 
Adjusted earnings available to common shareholders $ 135  $ 251  $ 159  $ 184  $ 215 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 1,087  $ 1,175  $ 1,224  $ 1,227  $ 1,372 
Adjusted earnings available to common shareholders, on a constant currency basis $ 142  $ 268  $ 179  $ 200  $ 215 

20

EMEA
STATEMENTS OF ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS
 
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Adjusted revenues
Premiums $ 509  $ 493  $ 472  $ 488  $ 496  $ 509  $ 496 
Universal life and investment-type product policy fees 83  77  57  67  77  83  77 
Net investment income 41  38  40  41  45  41  45 
Other revenues 10 
Total adjusted revenues 642  616  577  606  626  642  626 
Adjusted expenses
Policyholder benefits and claims and policyholder dividends 276  226  235  239  261  276  261 
Policyholder liability remeasurement (gains) losses (11) (5) (3) (3)
Interest credited to policyholder account balances 17  20  16  18  16  17  16 
Capitalization of DAC (101) (108) (96) (106) (108) (101) (108)
Amortization of DAC and VOBA 79  88  75  81  85  79  85 
Amortization of negative VOBA (1) (2) (1) (1) (1) (1) (1)
Interest expense on debt —  —  —  —  —  —  — 
Other expenses 296  298  269  308  300  296  300 
Total adjusted expenses 570  528  487  534  550  570  550 
Adjusted earnings before provision for income tax 72  88  90  72  76  72  76 
Provision for income tax expense (benefit) 17  22  26  16  17  16 
Adjusted earnings 55  66  64  64  60  55  60 
Preferred stock dividends —  —  —  —  —  —  — 
Adjusted earnings available to common shareholders $ 55  $ 66  $ 64  $ 64  $ 60  $ 55  $ 60 
Adjusted premiums, fees and other revenues $ 601  $ 578  $ 537  $ 565  $ 581  $ 601  $ 581 
21

EMEA
OTHER EXPENSES BY MAJOR CATEGORY
For the Three Months Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Direct and allocated expenses $ 97  $ 101  $ 91  $ 100  $ 94 
Pension, postretirement and postemployment benefit costs
Premium taxes, other taxes, and licenses & fees
Commissions and other variable expenses 192  191  174  201  200 
Adjusted other expenses $ 296  $ 298  $ 269  $ 308  $ 300 
Adjusted other expenses, net of adjusted capitalization of DAC $ 195  $ 190  $ 173  $ 202  $ 192 
Adjusted other expenses on a constant currency basis $ 276  $ 289  $ 272  $ 314  $ 300 
Adjusted other expenses, net of adjusted capitalization of DAC, on a constant currency basis $ 182  $ 185  $ 173  $ 205  $ 192 
OTHER STATISTICAL INFORMATION
   For the Three Months Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Adjusted premiums, fees and other revenues $ 601  $ 578  $ 537  $ 565  $ 581 
Adjusted earnings available to common shareholders $ 55  $ 66  $ 64  $ 64  $ 60 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 551  $ 555  $ 539  $ 572  $ 581 
Adjusted earnings available to common shareholders, on a constant currency basis $ 46  $ 60  $ 65  $ 66  $ 60 
Total sales on a constant currency basis $ 209  $ 208  $ 172  $ 187  $ 266 
22

METLIFE HOLDINGS
STATEMENTS OF ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Adjusted revenues
Premiums $ 776  $ 760  $ 745  $ 785  $ 723  $ 776  $ 723 
Universal life and investment-type product policy fees 228  296  202  176  183  228  183 
Net investment income 1,393  1,268  1,103  1,150  1,127  1,393  1,127 
Other revenues 44  23  39  49  53  44  53 
Total adjusted revenues 2,441  2,347  2,089  2,160  2,086  2,441  2,086 
Adjusted expenses
Policyholder benefits and claims and policyholder dividends 1,482  1,354  1,385  1,415  1,369  1,482  1,369 
Policyholder liability remeasurement (gains) losses 16  74  20  16  20 
Interest credited to policyholder account balances 202  203  202  206  199  202  199 
Capitalization of DAC (6) (7) (9) (7) (6) (6) (6)
Amortization of DAC and VOBA 75  70  64  61  68  75  68 
Amortization of negative VOBA —  —  —  —  —  —  — 
Interest expense on debt
Other expenses 236  242  228  247  238  236  238 
Total adjusted expenses 2,006  1,868  1,946  1,932  1,891  2,006  1,891 
Adjusted earnings before provision for income tax 435  479  143  228  195  435  195 
Provision for income tax expense (benefit) 87  97  26  44  37  87  37 
Adjusted earnings 348  382  117  184  158  348  158 
Preferred stock dividends —  —  —  —  —  —  — 
Adjusted earnings available to common shareholders $ 348  $ 382  $ 117  $ 184  $ 158  $ 348  $ 158 
Adjusted premiums, fees and other revenues $ 1,048  $ 1,079  $ 986  $ 1,010  $ 959  $ 1,048  $ 959 
23

METLIFE HOLDINGS
FUTURE POLICY BENEFITS (1)
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Annuities $ 1,842  $ 1,696  $ 1,582  $ 1,593  $ 1,606 
Life and Other 55,080  54,830  54,605  54,573  54,365 
Long Term Care 17,755  14,828  12,986  13,845  14,617 
Balance, end of period (at balance sheet discount rate) (2) $ 74,677  $ 71,354  $ 69,173  $ 70,011  $ 70,588 
Less:
Annuities $ 136  $ 12  $ (89) $ (60) $ (29)
Life and Other 233  41  (93) (60) (16)
Long Term Care 3,881  800  (1,217) (513) 111 
Accumulated other comprehensive (income) loss $ 4,250  $ 853  $ (1,399) $ (633) $ 66 
Annuities $ 1,706  $ 1,684  $ 1,671  $ 1,653  $ 1,635 
Life and Other 54,847  54,789  54,698  54,633  54,381 
Long Term Care 13,874  14,028  14,203  14,358  14,506 
Balance, end of period (at original discount rate) $ 70,427  $ 70,501  $ 70,572  $ 70,644  $ 70,522 
POLICYHOLDER ACCOUNT BALANCES
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Annuities $ 14,182  $ 13,985  $ 13,701  $ 13,286  $ 12,818 
Life and Other 12,676  12,607  12,544  12,402  12,234 
Balance, end of period $ 26,858  $ 26,592  $ 26,245  $ 25,688  $ 25,052 
MARKET RISK BENEFITS (3)
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Annuities $ 4,820  $ 4,256  $ 3,534  $ 3,225  $ 3,361 
Balance, end of period $ 4,820  $ 4,256  $ 3,534  $ 3,225  $ 3,361 
SEPARATE ACCOUNT LIABILITIES
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Annuities $ 36,079  $ 30,163  $ 27,680  $ 28,499  $ 29,320 
Life and Other 6,776  5,527  5,225  5,475  5,794 
Balance, end of period $ 42,855  $ 35,690  $ 32,905  $ 33,974  $ 35,114 
(1) Includes participating life contracts. additional liabilities for annuitization, death and other insurance benefits, as well as DPL.
(2) Represents the current discount rate at the respective balance sheet date.
(3) Market risk benefits include Japan reinsurance.
24

METLIFE HOLDINGS
OTHER EXPENSES BY MAJOR CATEGORY
   For the Three Months Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Direct and allocated expenses $ 167  $ 160  $ 164  $ 178  $ 171 
Pension, postretirement and postemployment benefit costs — 
Premium taxes, other taxes, and licenses & fees 16  17  20  15  18 
Commissions and other variable expenses 52  64  44  53  43 
Adjusted other expenses $ 236  $ 242  $ 228  $ 247  $ 238 
OTHER STATISTICAL INFORMATION
For the Three Months Ended
Unaudited (In millions, except ratios) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Life (1)
Adjusted premiums, fees and other revenues $ 692  $ 745  $ 654  $ 694  $ 639 
Interest adjusted benefit ratio 54.1  % 33.2  % 53.9  % 49.1  % 45.8  %
Lapse Ratio (2)
Traditional life 4.2  % 4.4  % 4.5  % 4.6  % 4.7  %
Variable & universal life 3.4  % 3.3  % 3.3  % 3.4  % 3.5  %
Fixed annuity 6.3  % 6.2  % 6.6  % 7.3  % 9.0  %
Variable annuity 10.0  % 9.8  % 9.5  % 9.2  % 9.5  %
(1) Represents the traditional life and variable & universal life components of Life & Other. Results are derived from insurance contracts.                                        
(2) Lapse ratios are calculated based on the average of the most recent 12 months of experience.

25

CORPORATE & OTHER
STATEMENTS OF ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Adjusted revenues
Premiums $ (4) $ (6) $ (7) $ $ 16  $ (4) $ 16 
Universal life and investment-type product policy fees —  (1) —  —  — 
Net investment income 120  17  78  58  50  120  50 
Other revenues 101  98  96  101  101  101  101 
Total adjusted revenues 217  111  166  161  167  217  167 
Adjusted expenses
Policyholder benefits and claims and policyholder dividends (7) (2) (3) 16  (7) 16 
Policyholder liability remeasurement (gains) losses —  —  —  —  —  —  — 
Interest credited to policyholder account balances —  —  —  —  —  —  — 
Capitalization of DAC (3) (2) (2) (1) (1) (3) (1)
Amortization of DAC and VOBA
Amortization of negative VOBA —  —  —  —  —  —  — 
Interest expense on debt 219  219  231  240  247  219  247 
Other expenses 136  184  186  203  177  136  177 
Total adjusted expenses 347  401  415  450  440  347  440 
Adjusted earnings before provision for income tax (130) (290) (249) (289) (273) (130) (273)
Provision for income tax expense (benefit) (88) (92) (55) (108) (103) (88) (103)
Adjusted earnings (42) (198) (194) (181) (170) (42) (170)
Preferred stock dividends 63  29  64  29  66  63  66 
Adjusted earnings available to common shareholders $ (105) $ (227) $ (258) $ (210) $ (236) $ (105) $ (236)
Adjusted premiums, fees and other revenues $ 97  $ 94  $ 88  $ 103  $ 117  $ 97  $ 117 
ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS BY SOURCE
   For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Business activities $ 36  $ 34  $ 36  $ 32  $ 19  $ 36  $ 19 
Net investment income 120  18  75  63  51  120  51 
Interest expense on debt (227) (226) (240) (250) (258) (227) (258)
Corporate initiatives and projects (12) (21) (15) (16) (14) (12) (14)
Other (47) (95) (105) (118) (71) (47) (71)
Provision for income tax (expense) benefit and other tax-related items 88  92  55  108  103  88  103 
Preferred stock dividends (63) (29) (64) (29) (66) (63) (66)
Adjusted earnings available to common shareholders $ (105) $ (227) $ (258) $ (210) $ (236) $ (105) $ (236)
26

INVESTMENTS
INVESTMENT PORTFOLIO RESULTS BY ASSET CATEGORY AND ANNUALIZED YIELDS
This yield table presentation is consistent with how we measure our investment performance for management purposes, and we believe it enhances understanding of our investment portfolio results.
At or For the Three Months Ended (1) At or For the Year-to-Date Period Ended (1)
Unaudited (In millions, except yields) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Fixed Maturity Securities
Yield 3.52  % 3.66  % 3.81  % 4.04  % 4.07  % 3.52  % 4.07  %
Investment income (2), (3) $ 2,638  $ 2,709  $ 2,773  $ 2,978  $ 3,028  $ 2,638  $ 3,028 
Investment gains (losses) (599) (671) (286) (356) (580) (599) (580)
Ending carrying value (4) 321,656  285,573  272,079  278,215  285,397  321,656  285,397 
Mortgage Loans
Yield 4.13  % 4.11  % 4.37  % 4.73  % 4.92  % 4.13  % 4.92  %
Investment income (3) 823  832  898  983  1,041  823  1,041 
Investment gains (losses) 44  48  47  (118) (164) 44  (164)
Ending carrying value 79,968  82,055  82,437  83,763  85,572  79,968  85,572 
Real Estate and Real Estate Joint Ventures
Yield 7.82  % 8.98  % 5.75  % 3.16  % (2.10) % 7.82  % (2.10) %
Investment income 241  277  179  101  (69) 241  (69)
Investment gains (losses) 159  —  490  18  18 
Ending carrying value 12,379  12,376  12,532  13,137  13,155  12,379  13,155 
Policy Loans
Yield 5.13  % 5.09  % 5.18  % 5.22  % 5.35  % 5.13  % 5.35  %
Investment income 116  114  114  115  119  116  119 
Ending carrying value 9,036  8,876  8,783  8,874  8,863  9,036  8,863 
Equity Securities
Yield 3.48  % 2.46  % 6.40  % 3.58  % 3.17  % 3.48  % 3.17  %
Investment income 14  10  12  12 
Investment gains (losses) (50) (42) (23) (18) 48  (50) 48 
Ending carrying value 988  1,085  973  1,684  1,695  988  1,695 
Other Limited Partnership Interests
Yield (5) 25.35  % 4.69  % (5.35) % (1.18) % 0.73  % 25.35  % 0.73  %
Investment income (5) 926  171  (194) (43) 26  926  26 
Investment gains (losses) 18  (2) (1) 38  18 
Ending carrying value (6) 14,570  14,636  14,387  14,414  14,437  14,570  14,437 
Cash and Short-term Investments
Yield 1.08  % 1.53  % 2.54  % 3.70  % 5.01  % 1.08  % 5.01  %
Investment income 30  43  78  131  167  30  167 
Investment gains (losses) 14  42  63  (37) (11) 14  (11)
Ending carrying value 26,634  23,591  27,466  25,130  22,640  26,634  22,640 
Other Invested Assets
Investment income 364  484  426  396  439  364  439 
Investment gains (losses) 47  69  (14) (15) (11) 47  (11)
Ending carrying value 18,696  19,901  22,299  20,038  19,479  18,696  19,479 
Total Investments
Investment income yield 4.72  % 4.29  % 3.98  % 4.27  % 4.31  % 4.72  % 4.31  %
Investment fees and expenses yield (0.13) % (0.12) % (0.12) % (0.13) % (0.14) % (0.13) % (0.14) %
Net Investment Income Yield 4.59  % 4.17  % 3.86  % 4.14  % 4.17  % 4.59  % 4.17  %
Investment income $ 5,145  $ 4,635  $ 4,288  $ 4,671  $ 4,763  $ 5,145  $ 4,763 
Investment fees and expenses (142) (131) (125) (141) (157) (142) (157)
Net investment income including divested businesses 5,003  4,504  4,163  4,530  4,606  5,003  4,606 
Less: Net investment income from divested businesses 11  —  —  —  —  11  — 
Adjusted Net Investment Income (7) $ 4,992  $ 4,504  $ 4,163  $ 4,530  $ 4,606  $ 4,992  $ 4,606 
Ending Carrying Value $ 483,927  $ 448,093  $ 440,956  $ 445,255  $ 451,238  $ 483,927  $ 451,238 
Investment Portfolio Gains (Losses) (8) $ (522) $ (397) $ (214) $ (16) $ (691) $ (522) $ (691)
Gross investment gains 310  597  259  1,117  433  310  433 
Gross investment losses (548) (1,084) (541) (1,084) (936) (548) (936)
Net credit loss (provision) release and (impairments) (284) 90  68  (49) (188) (284) (188)
Investment Portfolio Gains (Losses) (8) (522) (397) (214) (16) (691) (522) (691)
Investment portfolio gains (losses) income tax (expense) benefit 116  92  51  181  116  181 
Investment Portfolio Gains (Losses), Net of Income Tax $ (406) $ (305) $ (163) $ (13) $ (510) $ (406) $ (510)
Derivative gains (losses) (8) (1,166) (1,202) (478) (381) (372) (1,166) (372)
Derivative gains (losses) income tax (expense) benefit 275  355  129  69  47  275  47 
Derivative Gains (Losses), Net of Income Tax $ (891) $ (847) $ (349) $ (312) $ (325) $ (891) $ (325)
See footnotes on Page 30.

27

INVESTMENTS
 
SUMMARY OF FIXED MATURITY SECURITIES AVAILABLE-FOR-SALE
BY SECTOR AND QUALITY DISTRIBUTION
March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Unaudited (In millions, except ratios) Amount % of Total Amount % of Total Amount % of Total Amount % of Total Amount % of Total
U.S. corporate $ 87,136  27.2  % $ 80,555  28.3  % $ 78,824  29.1  % $ 80,030  28.9  % $ 82,482  29.1  %
Foreign corporate 61,129  19.1  % 54,177  19.1  % 49,927  18.4  % 52,572  19.0  % 54,285  19.1  %
Foreign government 57,282  17.9  % 48,016  16.9  % 44,050  16.3  % 46,747  16.9  % 48,111  16.9  %
U.S. government and agency 40,334  12.6  % 33,690  11.9  % 31,562  11.7  % 32,229  11.6  % 32,878  11.6  %
Residential mortgage-backed 30,080  9.4  % 27,303  9.6  % 27,145  10.0  % 26,165  9.5  % 26,543  9.4  %
Asset-backed securities and collateralized loan obligations 19,305  6.0  % 17,054  6.0  % 16,766  6.2  % 16,822  6.1  % 16,970  6.0  %
Municipals 12,958  4.1  % 12,513  4.4  % 12,014  4.4  % 12,152  4.4  % 12,597  4.4  %
Commercial mortgage-backed 11,855  3.7  % 10,870  3.8  % 10,477  3.9  % 10,063  3.6  % 9,988  3.5  %
Fixed Maturity Securities Available-For-Sale $ 320,079  100.0  % $ 284,178  100.0  % $ 270,765  100.0  % $ 276,780  100.0  % $ 283,854  100.0  %
NRSRO NAIC
RATING DESIGNATION
Aaa / Aa / A 1 $ 222,096  69.4  % $ 195,090  68.7  % $ 185,780  68.6  % $ 190,021  68.7  % $ 195,535  69.0  %
Baa 2 82,616  25.8  % 74,783  26.3  % 71,276  26.3  % 73,194  26.5  % 74,661  26.3  %
Ba 3 11,788  3.7  % 11,129  3.9  % 10,652  4.0  % 10,511  3.8  % 10,856  3.8  %
B 4 2,923  0.9  % 2,653  0.9  % 2,618  1.0  % 2,571  0.9  % 2,296  0.8  %
Caa and lower 5 480  0.1  % 389  0.2  % 306  0.1  % 401  0.1  % 395  0.1  %
In or near default 6 176  0.1  % 134  —  % 133  —  % 82  —  % 111  —  %
Total Fixed Maturity Securities Available-For-Sale (9) $ 320,079  100.0  % $ 284,178  100.0  % $ 270,765  100.0  % $ 276,780  100.0  % $ 283,854  100.0  %
GROSS UNREALIZED GAINS AND LOSSES
FIXED MATURITY SECURITIES AVAILABLE-FOR-SALE
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Gross unrealized gains $ 16,145  $ 8,666  $ 5,488  $ 5,239  $ 6,554 
Gross unrealized losses 9,583  23,759  36,982  34,301  27,469 
Net Unrealized Gains (Losses) $ 6,562  $ (15,093) $ (31,494) $ (29,062) $ (20,915)
See footnotes on Page 30.

28

INVESTMENTS
SUMMARY OF MORTGAGE LOANS
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
              
Commercial mortgage loans $ 51,117  $ 52,348  $ 52,273  $ 52,502  $ 53,697 
Agricultural mortgage loans 17,882  18,563  18,923  19,306  19,361 
Residential mortgage loans 11,584  11,606  11,708  12,482  13,206 
Mortgage loans held-for-sale —  24  —  —  — 
Mortgage Loans 80,583  82,541  82,904  84,290  86,264 
Allowance for credit loss (615) (486) (467) (527) (692)
Mortgage Loans, net $ 79,968  $ 82,055  $ 82,437  $ 83,763  $ 85,572 
SUMMARY OF COMMERCIAL MORTGAGE LOANS
BY REGION AND PROPERTY TYPE
 
March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Unaudited (In millions, except ratios) Amount % of Total Amount % of Total Amount % of Total Amount % of Total Amount % of Total
Pacific $ 9,824  19.2  % $ 9,901  18.9  % $ 9,805  18.7  % $ 9,628  18.3  % $ 9,736  18.1  %
Non-U.S. 10,064  19.7  % 9,726  18.6  % 8,977  17.2  % 9,299  17.7  % 9,383  17.5  %
Middle Atlantic 7,876  15.4  % 7,918  15.1  % 7,748  14.8  % 7,574  14.4  % 7,647  14.2  %
South Atlantic 6,849  13.4  % 6,852  13.1  % 6,691  12.8  % 6,617  12.6  % 6,671  12.4  %
West South Central 3,587  7.0  % 3,943  7.5  % 4,005  7.7  % 3,721  7.1  % 3,765  7.0  %
New England 2,752  5.4  % 2,781  5.3  % 2,754  5.3  % 2,764  5.3  % 2,876  5.4  %
Mountain 2,078  4.1  % 2,268  4.3  % 2,269  4.3  % 2,284  4.4  % 2,284  4.3  %
East North Central 2,013  3.9  % 1,489  2.9  % 1,596  3.1  % 1,594  3.0  % 1,768  3.3  %
East South Central 725  1.4  % 636  1.2  % 635  1.2  % 620  1.2  % 624  1.2  %
West North Central 458  0.9  % 428  0.8  % 471  0.9  % 597  1.1  % 596  1.1  %
Multi-Region and Other 4,891  9.6  % 6,406  12.3  % 7,322  14.0  % 7,804  14.9  % 8,347  15.5  %
Total $ 51,117  100.0  % $ 52,348  100.0  % $ 52,273  100.0  % $ 52,502  100.0  % $ 53,697  100.0  %
Office $ 22,170  43.4  % $ 21,923  41.9  % $ 21,144  40.5  % $ 21,009  40.0  % $ 21,134  39.4  %
Apartment 9,578  18.7  % 10,536  20.1  % 10,793  20.6  % 10,575  20.2  % 11,357  21.2  %
Retail 8,766  17.2  % 8,524  16.3  % 8,305  15.9  % 8,046  15.3  % 8,289  15.4  %
Industrial 5,055  9.9  % 4,902  9.4  % 5,068  9.7  % 5,607  10.7  % 5,219  9.7  %
Hotel 3,137  6.1  % 3,323  6.3  % 3,261  6.2  % 3,172  6.0  % 3,117  5.8  %
Other 2,411  4.7  % 3,140  6.0  % 3,702  7.1  % 4,093  7.8  % 4,581  8.5  %
Total $ 51,117  100.0  % $ 52,348  100.0  % $ 52,273  100.0  % $ 52,502  100.0  % $ 53,697  100.0  %
29

INVESTMENTS
FOOTNOTES
(1)We calculate yields using adjusted net investment income as a percent of average quarterly asset carrying values. Adjusted net investment income excludes realized gains and losses from sales and disposals, includes the impact of changes in foreign currency exchange rates and reflects the adjustments described on Page A-7 and presented on Page A-1. Average quarterly asset carrying values exclude unrealized gains (losses), collateral received in connection with our securities lending program, annuities funding structured settlement claims, freestanding derivative assets, collateral received from derivative counterparties and contractholder-directed equity securities. In addition, average quarterly asset carrying values include invested assets reclassified to held-for-sale, while ending carrying values exclude invested assets reclassified to held-for-sale. A yield is not presented for other invested assets, as it is not considered a meaningful measure of performance for this asset class.
(2)Fixed maturity securities includes investment income related to fair value option securities of ($65) million, ($89) million, ($43) million, $70 million and $48 million for the three months ended March 31, 2022, June 30, 2022, September 30, 2022, December 31, 2022, and March 31,2023, respectively, and ($65) million and $48 million for the year-to-date period ended March 31, 2022 and March 31, 2023, respectively.
(3)Investment income from fixed maturity securities and mortgage loans includes prepayment fees.
(4)The following table presents the components of total fixed maturity securities and a reconciliation to ending carrying value presented for fixed maturity securities.
March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Fixed maturity securities available-for-sale $ 320,079  $ 284,178  $ 270,765  $ 276,780  $ 283,854 
Contractholder-directed equity securities and fair value option securities 11,418  9,875  8,954  9,668  10,063 
Total fixed maturity securities 331,497  294,053  279,719  286,448  293,917 
Less: Contractholder-directed equity securities 9,841  8,480  7,640  8,233  8,520 
Fixed maturity securities $ 321,656  $ 285,573  $ 272,079  $ 278,215  $ 285,397 
(5)Other limited partnership interests includes investment income related to private equity investments of $984 million, $216 million, ($188) million, ($40) million and $17 million for the three months ended March 31, 2022, June 30, 2022, September 30, 2022, December 31, 2022 and March 31, 2023 , respectively, and $984 million and $17 million for the year-to-date period ended March 31, 2022 and March 31, 2023, respectively. The annualized yields for these periods were 28.16%, 6.17%, (5.37%), (1.15%), 0.48%, 28.16% and 0.48%, respectively.
(6)Other limited partnership interests includes ending carrying value related to private equity investments of $13,971 million, $14,092 million, $13,855 million, $14,000 million and $14,225 million at March 31, 2022, June 30, 2022, September 30, 2022, December 31, 2022 and March 31, 2023, respectively.
(7)Adjusted net investment income reflects the adjustments as presented on Page 5.
(8)Investment portfolio gains (losses) and Derivative gains (losses) reflect the non-GAAP adjustments as presented below:
For the Three Months Ended For the Year-to-Date Period Ended
March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Net investment gains (losses) $ (517) $ (682) $ (411) $ 350  $ (684) $ (517) $ (684)
Less: Operating joint venture adjustments (1) (1) $ (1) (1)
Less: Change in estimated fair value of other limited partnership interests and real estate joint ventures (1) (18) (2) (5) (5)
Less: Non-investment portfolio gains (losses) (8) (283) (184) 369  13  (8) 13 
Investment portfolio gains (losses) $ (522) $ (397) $ (214) $ (16) $ (691) $ (522) $ (691)
For the Three Months Ended For the Year-to-Date Period Ended
March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Net derivative gains (losses) $ (951) $ (970) $ (226) $ (104) $ (90) $ (951) $ (90)
Less: Investment hedge adjustments 215  232  252  277  264  215  264 
Less: Other adjustments —  —  —  —  18  —  18 
Derivative gains (losses) $ (1,166) $ (1,202) $ (478) $ (381) $ (372) $ (1,166) $ (372)
(9)Fixed maturity securities available-for-sale are presented by NRSRO rating and the applicable NAIC designation from the NAIC published comparison of NRSRO ratings to NAIC designations, except for (i) non-agency residential mortgage-backed securities (“RMBS”) and commercial mortgage-backed securities (“CMBS”) and (ii) securities rated Ca or C by NRSROs that are designated NAIC 6. NRSRO ratings are based on availability of applicable ratings. If no NRSRO rating is available, then an internally developed rating is used. Over time, credit ratings can migrate, up or down, through the NRSRO's and NAIC's continuous monitoring process. Amounts presented for non-agency RMBS and CMBS are presented using NAIC designations for modeled securities. The NAIC evaluates non-agency RMBS and CMBS held by insurers on an annual basis. When we acquire non-agency RMBS and CMBS that have not been previously evaluated by the NAIC, an internally developed designation is used until a NAIC designation becomes available. NAIC designations are generally similar to the credit quality ratings of the NRSRO, except for (i) non-agency RMBS and CMBS and (ii) securities rated Ca or C by NRSROs that are designated NAIC 6; accordingly, NAIC designations may not correspond to NRSRO ratings.
30

image0a45.jpg
Appendix




A-1

APPENDIX
METLIFE
RECONCILIATION DETAIL
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Reconciliation to Adjusted Earnings Available to Common Shareholders
Net income (loss) available to MetLife, Inc.'s common shareholders $ 1,571  $ 881  $ 1,098  $ 1,549  $ 14  $ 1,571  $ 14 
Add: Preferred stock dividends 63  29  64  29  66  63  66 
Add: Preferred stock redemption premium —  —  —  —  —  —  — 
Add: Net Income (loss) attributable to noncontrolling interests
Net income (loss) 1,639  915  1,167  1,581  85  $ 1,639  $ 85 
Less: adjustments from net income (loss) to adjusted earnings:
Net investment gains (losses) (517) (682) (411) 350  (684) (517) (684)
Net derivative gains (losses) (951) (970) (226) (104) (90) (951) (90)
Market risk benefit remeasurement gains (losses) 1,440  757  965  512  (188) 1,440  (188)
Premiums - Divested businesses
41  —  —  —  —  41  — 
Universal life and investment-type product policy fees - Divested businesses
11  —  —  —  —  11  — 
Net investment income
Investment hedge adjustments (215) (232) (252) (277) (264) (215) (264)
Unit-linked contract income (498) (688) (321) 209  303  (498) 303 
Other adjustments (6) (1) (5) —  (6) — 
Divested businesses 11  —  —  —  —  11  — 
Other revenues
Asymmetrical and non-economic accounting —  —  —  —  —  —  — 
Other adjustments 47  48  40  25  (3) 47  (3)
Divested businesses —  —  —  —  — 
Policyholder benefits and claims and policyholder dividends
Asymmetrical and non-economic accounting (119) (215) (241) (79) (84) (119) (84)
Market volatility (12) 34  66  105  14  (12) 14 
Divested businesses (23) —  —  —  —  (23) — 
Policyholder liability remeasurement (gains) losses - Divested businesses
—  —  —  —  —  —  — 
Interest credited to policyholder account balances
Asymmetrical and non-economic accounting 63  31  36  (64) (19) 63  (19)
Unit-linked contract costs 505  695  302  (180) (303) 505  (303)
Divested businesses (3) —  —  —  —  (3) — 
Capitalization of DAC - Divested businesses
11  —  —  —  —  11  — 
Amortization of DAC and VOBA - Divested businesses
(8) —  —  —  —  (8) — 
Amortization of negative VOBA - Divested business
—  —  —  —  —  —  — 
Interest expense on debt - Divested business
—  —  —  —  —  —  — 
Other expenses
Other adjustments (47) (60) (47) (37) (16) (47) (16)
Divested businesses (32) (8) (13) (21) (11) (32) (11)
Goodwill impairment —  —  —  —  —  —  — 
Provision for income tax (expense) benefit 180  439  110  (149) 180  180  180 
Adjusted earnings 1,758  1,767  1,164  1,289  1,250  1,758  1,250 
Less: Preferred stock dividends 63  29  64  29  66  63  66 
Adjusted earnings available to common shareholders $ 1,695  $ 1,738  $ 1,100  $ 1,260  $ 1,184  $ 1,695  $ 1,184 
A-1

APPENDIX
METLIFE
NOTABLE ITEMS (1)
METLIFE TOTAL
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Actuarial assumption review and other insurance adjustments $ —  $ 77  $ 12  $ —  $ —  $ —  $ — 
Total notable items $ —  $ 77  $ 12  $ —  $ —  $ —  $ — 
U.S.
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Actuarial assumption review and other insurance adjustments $ —  $ —  $ 79  $ —  $ —  $ —  $ — 
Total notable items $ —  $ —  $ 79  $ —  $ —  $ —  $ — 
GROUP BENEFITS
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Actuarial assumption review and other insurance adjustments $ —  $ —  $ —  $ —  $ —  $ —  $ — 
Total notable items $ —  $ —  $ —  $ —  $ —  $ —  $ — 
RETIREMENT AND INCOME SOLUTIONS
   For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Actuarial assumption review and other insurance adjustments $ —  $ —  $ 79  $ —  $ —  $ —  $ — 
Total notable items $ —  $ —  $ 79  $ —  $ —  $ —  $ — 
(1)These notable items represent a positive (negative) impact to adjusted earnings available to common shareholders. Notable items reflect the unexpected impact of events that affect MetLife's results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results.
A-2

APPENDIX
METLIFE
NOTABLE ITEMS (1) CONTINUED
ASIA
   For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Actuarial assumption review and other insurance adjustments
$ —  $ —  $ (32) $ —  $ —  $ —  $ — 
Total notable items
$ —  $ —  $ (32) $ —  $ —  $ —  $ — 
LATIN AMERICA
  
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions)
March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Actuarial assumption review and other insurance adjustments
$ —  $ —  $ $ —  $ —  $ —  $ — 
Total notable items
$ —  $ —  $ $ —  $ —  $ —  $ — 
EMEA
  
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions)
March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Actuarial assumption review and other insurance adjustments
$ —  $ —  $ 15  $ —  $ —  $ —  $ — 
Total notable items
$ —  $ —  $ 15  $ —  $ —  $ —  $ — 
METLIFE HOLDINGS
  
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions)
March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 March 31, 2022 March 31, 2023
Actuarial assumption review and other insurance adjustments
$ —  $ 77  $ (51) $ —  $ —  $ —  $ — 
Total notable items
$ —  $ 77  $ (51) $ —  $ —  $ —  $ — 
(1)These notable items represent a positive (negative) impact to adjusted earnings available to common shareholders. Notable items reflect the unexpected impact of events that affect MetLife's results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results.
A-3

APPENDIX
METLIFE
EQUITY DETAILS, BOOK VALUE DETAILS AND RETURN ON EQUITY
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Total MetLife, Inc.'s stockholders' equity $ 42,432  $ 33,744  $ 29,389  $ 29,881  $ 32,194 
Less: Preferred stock 3,818  3,818  3,818  3,818  3,818 
MetLife, Inc.'s common stockholders' equity 38,614  29,926  25,571  26,063  28,376 
Less: Net unrealized investment gains (losses), net of income tax 6,083  (10,289) (21,652) (21,089) (14,606)
  Future policy benefits discount rate remeasurement gains (losses), net of income tax (9,248) (136) 7,612  6,115  2,748 
  Market risk benefits instrument-specific credit risk remeasurement gains (losses), net of income tax 195  193  174  107  186 
  Defined benefit plans adjustment, net of income tax (1,577) (1,555) (1,536) (1,377) (1,356)
Total MetLife, Inc.'s common stockholders' equity, excluding AOCI other than FCTA 43,161  41,713  40,973  42,307  41,404 
Less: Accumulated year-to-date total notable items (2) —  77  89  89  — 
Total MetLife, Inc.'s common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA) (2) $ 43,161  $ 41,636  $ 40,884  $ 42,218  $ 41,404 
Unaudited (In millions, except per share data) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Book value per common share $ 47.39  $ 37.52  $ 32.48  $ 33.45  $ 36.89 
Less: Net unrealized investment gains (losses), net of income tax 7.47  (12.90) (27.50) (27.07) (18.99)
  Future policy benefits discount rate remeasurement gains (losses), net of income tax (11.36) (0.17) 9.67  7.85  3.57 
  Market risk benefits instrument-specific credit risk remeasurement gains (losses), net of income tax 0.24  0.24  0.22  0.14  0.24 
  Defined benefit plans adjustment, net of income tax (1.93) (1.95) (1.95) (1.77) (1.76)
Book value per common share, excluding AOCI other than FCTA $ 52.97  $ 52.30  $ 52.04  $ 54.30  $ 53.83 
Common shares outstanding, end of period 814.8  797.6  787.3  779.1  769.2 
For the Three Months Ended (1)
Unaudited (In millions, except ratios) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Return on MetLife, Inc.'s:
Common stockholders' equity 14.9  % 10.3  % 15.8  % 24.0  % 0.2  %
Adjusted return on MetLife, Inc.'s:
Common stockholders' equity 16.0  % 20.3  % 15.9  % 19.5  % 17.4  %
Common stockholders' equity, excluding AOCI other than FCTA 15.7  % 16.4  % 10.6  % 12.1  % 11.3  %
Common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA) (2) 15.7  % 15.7  % 10.5  % 12.1  % 11.3  %
Average common stockholders' equity $ 42,272  $ 34,270  $ 27,749  $ 25,817  $ 27,220 
Average common stockholders' equity, excluding AOCI other than FCTA $ 43,210  $ 42,437  $ 41,343  $ 41,640  $ 41,856 
Average common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA) (2) $ 43,210  $ 42,399  $ 41,260  $ 41,551  $ 41,856 
(1) Annualized using quarter-to-date results.
(2)Notable items reflect the unexpected impact of events that affect MetLife’s results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results. Notable items can affect MetLife’s results either positively or negatively. See Page A-2 for further detail.
A-4

APPENDIX
METLIFE
ADJUSTED PREMIUMS, FEES AND OTHER REVENUES, OTHER EXPENSES AND ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS - CONSTANT CURRENCY BASIS
 ADJUSTED PREMIUMS, FEES AND OTHER REVENUES, ON A CONSTANT CURRENCY BASIS
For the Three Months Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
U.S. (1) $ 7,729  $ 8,781  $ 14,754  $ 6,316  $ 6,697 
ASIA 1,792  1,795  1,856  1,814  1,794 
LATIN AMERICA 1,087  1,175  1,224  1,227  1,372 
EMEA 551  555  539  572  581 
METLIFE HOLDINGS (1) 1,048  1,079  986  1,010  959 
CORPORATE & OTHER (1) 97  94  88  103  117 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 12,304  $ 13,479  $ 19,447  $ 11,042  $ 11,520 
Adjusted premiums, fees and other revenues $ 12,487  $ 13,495  $ 19,295  $ 10,873  $ 11,520 
ASIA (including operating joint ventures) (2), (3) $ 2,164  $ 2,095  $ 2,246  $ 2,193  $ 2,293 
 OTHER EXPENSES ON A CONSTANT CURRENCY BASIS
For the Three Months Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
U.S. (1) $ 979  $ 949  $ 1,003  $ 1,031  $ 1,078 
ASIA 753  746  775  848  807 
LATIN AMERICA 362  373  407  452  430 
EMEA 276  289  272  314  300 
METLIFE HOLDINGS (1) 236  242  228  247  238 
CORPORATE & OTHER (1) 136  184  186  203  177 
Adjusted other expenses on a constant currency basis $ 2,742  $ 2,783  $ 2,871  $ 3,095  $ 3,030 
Adjusted other expenses $ 2,833  $ 2,800  $ 2,815  $ 3,020  $ 3,030 
ASIA (including operating joint ventures) (2), (4) $ 863  $ 848  $ 886  $ 959  $ 936 
 ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS ON A CONSTANT CURRENCY BASIS
For the Three Months Ended
Unaudited (In millions) March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
U.S. (1) $ 663  $ 780  $ 751  $ 773  $ 707 
ASIA 581  478  267  270  280 
LATIN AMERICA 142  268  179  200  215 
EMEA 46  60  65  66  60 
METLIFE HOLDINGS (1) 348  382  117  184  158 
CORPORATE & OTHER (1) (105) (227) (258) (210) (236)
Adjusted earnings available to common shareholders on a constant currency basis $ 1,675  $ 1,741  $ 1,121  $ 1,283  $ 1,184 
Adjusted earnings available to common shareholders $ 1,695  $ 1,738  $ 1,100  $ 1,260  $ 1,184 
(1) Amounts on a reported basis, as constant currency impact is not significant.
(2) Adjusted premiums, fees and other revenues as well as other expenses are reported as part of net investment income on the statements of adjusted earnings available to common shareholders on Page 16 for operating joint ventures.
(3) Includes MetLife, Inc.'s share of adjusted premiums, fees and other revenues for operating joint ventures of: (i) China, (ii) India, (iii) Malaysia and (iv) Vietnam, on the basis of proportional consolidation and MetLife's percentage ownership. These operating joint ventures are accounted for using the equity method of accounting under GAAP.
(4) Includes MetLife, Inc.'s share of adjusted other expenses for operating joint ventures of: (i) China, (ii) India, (iii) Malaysia and (iv) Vietnam, on the basis of proportional consolidation and MetLife's percentage ownership. These operating joint ventures are accounted for using the equity method of accounting under GAAP.
A-5

METLIFE
NON-GAAP AND OTHER FINANCIAL DISCLOSURES

In this QFS, MetLife presents certain measures of its performance on a consolidated and segment basis that are not calculated in accordance with GAAP. We believe that these non-GAAP financial measures enhance the understanding for MetLife and its investors of MetLife's performance by highlighting the results of operations and the underlying profitability drivers of our business. Segment-specific financial measures are calculated using only the portion of consolidated results attributable to that specific segment.

The following non-GAAP financial measures should not be viewed as substitutes for the most directly comparable financial measures calculated in accordance with GAAP:
Non-GAAP financial measures: Comparable GAAP financial measures:
(i) total adjusted revenues (i) total revenues
(ii) total adjusted expenses (ii) total expenses
(iii) adjusted premiums, fees and other revenues (iii) premiums, fees and other revenues
(iv) adjusted premiums, fees & other revenues, excluding PRT (iv) premiums, fees and other revenues
(v) adjusted net investment income (v) net investment income
(vi) adjusted earnings (vi) net income (loss)
(vii) adjusted earnings available to common shareholders (vii) net income (loss) available to MetLife, Inc.’s common shareholders
(viii) adjusted earnings available to common shareholders, excluding total notable items (viii) net income (loss) available to MetLife, Inc.’s common shareholders
(ix) adjusted earnings available to common shareholders per diluted common share (ix) net income (loss) available to MetLife, Inc.’s common shareholders per diluted common share
(x) adjusted earnings available to common shareholders, excluding total notable items, per diluted common share (x) net income (loss) available to MetLife, Inc.’s common shareholders per diluted common share
(xi) adjusted return on equity (xi) return on equity
(xii) adjusted return on equity, excluding AOCI other than FCTA (xii) return on equity
(xiii) adjusted return on equity, excluding total notable items (excludes AOCI other than FCTA) (xiii) return on equity
(xiv) investment portfolio gains (losses) (xiv) net investment gains (losses)
(xv) derivative gains (losses) (xv) net derivative gains (losses)
(xvi) adjusted capitalization of DAC (xvi) capitalization of DAC
(xvii) total MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA (xvii) total MetLife, Inc.’s stockholders’ equity
(xviii) total MetLife, Inc.’s common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA) (xviii) total MetLife, Inc.’s stockholders’ equity
(xix) book value per common share, excluding AOCI other than FCTA (xix) book value per common share
(xx) adjusted other expenses (xx) other expenses
(xxi) adjusted other expenses, net of adjusted capitalization of DAC (xxi) other expenses, net of capitalization of DAC
(xxii) adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses (xxii) other expenses, net of capitalization of DAC
(xxiii) adjusted expense ratio (xxiii) expense ratio
(xxiv) adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT (xxiv) expense ratio
(xxv) direct expenses (xxv) other expenses
(xxvi) direct expenses, excluding total notable items related to direct expenses (xxvi) other expenses
(xxvii) direct expense ratio (xxvii) expense ratio
(xxviii) direct expense ratio, excluding total notable items related to direct expenses and PRT (xxviii) expense ratio
(xxix) future policy benefits at original discount rate (xxix) future policy benefits at balance sheet discount rate
Any of these financial measures shown on a constant currency basis reflect the impact of changes in foreign currency exchange rates and are calculated using the average foreign currency exchange rates for the most recent period. As a result, comparable prior period amounts are updated each period to reflect the most recent period average foreign currency exchange rates.
Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in this QFS and in this period’s earnings news release, which is available at www.metlife.com.

A-6

METLIFE
NON-GAAP AND OTHER FINANCIAL DISCLOSURES (CONTINUED)
Our definitions of non-GAAP and other financial measures discussed in this QFS may differ from those used by other companies:

Adjusted earnings and related measures
adjusted earnings;
adjusted earnings available to common shareholders;
adjusted earnings available to common shareholders, excluding total notable items;
adjusted earnings available to common shareholders per diluted common share;
adjusted earnings available to common shareholders, excluding total notable items per diluted common share; and
adjusted earnings available to common shareholders on a constant currency basis.
These measures are used by management to evaluate performance and allocate resources. Consistent with GAAP guidance for segment reporting, adjusted earnings and components of, or other financial measures based on, adjusted earnings are also MetLife’s GAAP measures of segment performance. Adjusted earnings and other financial measures based on adjusted earnings are also the measures by which MetLife senior management’s and many other employees’ performance is evaluated for the purposes of determining their compensation under applicable compensation plans. Adjusted earnings and other financial measures based on adjusted earnings allow analysis of MetLife's performance relative to its business plan and facilitate comparisons to industry results.

Effective January 1, 2023, MetLife adopted ASU 2018-12, Financial Services - Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts, as amended ("LDTI"), with a transition date of January 1, 2021, which impacted the calculation of adjusted earnings. With the adoption of LDTI, the measurement model was simplified for DAC and VOBA, and most embedded derivatives were reclassified as market risk benefits. As a result, MetLife updated its calculation of adjusted earnings to remove certain adjustments related to the amortization of DAC, VOBA and related intangibles and adjusted for changes in measurement of certain guarantees. Under LDTI, adjusted earnings excludes changes in fair value associated with market risk benefits, changes in discount rates on certain annuitization guarantees, losses at contract inception for certain single premium business, and asymmetrical accounting associated with in-force reinsurance. All periods presented herein reflect the updated calculation of adjusted earnings.

Adjusted earnings is defined as adjusted revenues less adjusted expenses, net of income tax. Adjusted earnings available to common shareholders is defined as adjusted earnings less preferred stock dividends.
Adjusted revenues and adjusted expenses
These financial measures, along with the related adjusted premiums, fees and other revenues, focus on our primary businesses principally by excluding the impact of (i) market volatility which could distort trends, (ii) asymmetrical and non-economic accounting, and (iii) revenues and costs related to divested businesses, non-core products and certain entities required to be consolidated under GAAP. Also, these measures exclude results of discontinued operations under GAAP.

Market volatility can have a significant impact on MetLife’s financial results. Adjusted earnings excludes net investment gains (losses), net derivative gains (losses), market risk benefits remeasurement gains (losses) and goodwill impairments. Further, policyholder benefits and claims exclude (i) changes in the discount rate on certain annuitization guarantees accounted for as additional liabilities and (ii) market value adjustments.
Asymmetrical and non-economic accounting adjustments are made to the line items indicated in calculating adjusted earnings:
Net investment income includes earned income on derivatives and amortization of premium on derivatives that are hedges of investments or that are used to replicate certain investments, but do not qualify for hedge accounting treatment ("Investment hedge adjustments").
Other revenues include settlements of foreign currency earnings hedges.
Policyholder benefits and claims excludes (i) amortization of basis adjustments associated with de-designated fair value hedges of future policy benefits, (ii) inflation-indexed benefit adjustments associated with contracts backed by inflation-indexed investments, and (iii) non-economic losses incurred at contract inception for certain single premium annuity business. These losses are amortized into adjusted earnings within policyholder benefits and claims over the estimated lives of the contracts.
Interest credited to policyholder account balances excludes amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass-through adjustments.
Divested businesses are those that have been or will be sold or exited by MetLife but do not meet the discontinued operations criteria under GAAP. Divested businesses also include the net impact of transactions with exited businesses that have been eliminated in consolidation under GAAP and costs relating to businesses that have been or will be sold or exited by MetLife that do not meet the criteria to be included in results of discontinued operations under GAAP.
Other adjustments are made to the line items indicated in calculating adjusted earnings:
Net investment income and interest credited to policyholder account balances excludes certain amounts related to contractholder-directed equity securities ("Unit-linked contract income") and ("Unit-linked contract costs").
Other revenues include fee revenue on synthetic GICs accounted for as freestanding derivatives.
Other revenues exclude and other expenses include fees received in connection with services provided under transition service agreements.
Other expenses exclude (i) implementation of new insurance regulatory requirements and other costs, and (ii) acquisition, integration and other related costs. Other expenses include (i) deductions for net income attributable to noncontrolling interests, and (ii) benefits accrued on synthetic GICs accounted for as freestanding derivatives.
Adjusted earnings also excludes the recognition of certain contingent assets and liabilities that could not be recognized at acquisition or adjusted for during the measurement period under GAAP business combination accounting guidance.

The tax impact of the adjustments mentioned above are calculated net of the U.S. or foreign statutory tax rate, which could differ from MetLife's effective tax rate. Additionally, the provision for income tax (expense) benefit also includes the impact related to the timing of certain tax credits, as well as certain tax reforms.

In addition, adjusted earnings available to common shareholders excludes the impact of preferred stock redemption premium which is reported as a reduction to net income (loss) available to MetLife, Inc.’s common shareholders.
Investment portfolio gains (losses) and derivative gains (losses)

These are measures of investment and hedging activity. Investment portfolio gains (losses) principally excludes amounts that are reported within net investment gains (losses) but do not relate to the performance of the investment portfolio, such as gains (losses) on sales and divestitures of businesses, as well as investment portfolio gains (losses) of divested businesses. Derivative gains (losses) principally excludes earned income on derivatives and amortization of premium on derivatives, where such derivatives are either hedges of investments or are used to replicate certain investments, and where such derivatives do not qualify for hedge accounting. This earned income and amortization of premium is reported within adjusted earnings and not within derivative gains (losses).
A-7


METLIFE
NON-GAAP AND OTHER FINANCIAL DISCLOSURES (CONTINUED)
Return on equity and related measures
Total MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA: Total MetLife, Inc.’s common stockholders’ equity, excluding the net unrealized investment gains (losses), future policy benefits discount rate remeasurement gains (losses), market risk benefits instrument-specific credit risk remeasurement gains (losses) and defined benefit plans adjustment, components of AOCI, net of income tax.
Total MetLife, Inc.’s common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA): Total MetLife, Inc.’s common stockholders’ equity, excluding the net unrealized investment gains (losses), future policy benefits discount rate remeasurement gains (losses), market risk benefits instrument-specific credit risk remeasurement gains (losses), defined benefit plans adjustment, components of AOCI, and total notable items, net of income tax.
Return on MetLife, Inc.’s common stockholders’ equity: net income (loss) available to MetLife, Inc.’s common shareholders divided by MetLife, Inc.'s average common stockholders’ equity.
Adjusted return on MetLife, Inc.’s common stockholders’ equity: adjusted earnings available to common shareholders divided by MetLife, Inc.'s average common stockholders’ equity.
Adjusted return on MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA: adjusted earnings available to common shareholders divided by MetLife, Inc.'s average common stockholders’ equity, excluding AOCI other than FCTA.
Adjusted return on MetLife, Inc.’s common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA): adjusted earnings available to common shareholders, excluding total notable items, divided by MetLife, Inc.'s average common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA).
The above measures represent a level of equity consistent with the view that, in the ordinary course of business, we do not plan to sell most investments for the sole purpose of realizing gains or losses.
Expense ratio, direct expense ratio, adjusted expense ratio and related measures
Expense ratio: other expenses, net of capitalization of DAC, divided by premiums, fees and other revenues.
Direct expense ratio: adjusted direct expenses divided by adjusted premiums, fees and other revenues.
Direct expense ratio, excluding total notable items related to direct expenses and PRT: adjusted direct expenses, excluding total notable items related to direct expenses, divided by adjusted premiums, fees and other revenues, excluding PRT.
Adjusted expense ratio: adjusted other expenses, net of adjusted capitalization of DAC, divided by adjusted premiums, fees and other revenues.
Adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT: adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses, divided by adjusted premiums, fees and other revenues, excluding PRT.
Asia general account assets under management and related measures
Asia GA AUM is used by MetLife to describe assets in its Asia GA investment portfolio which are actively managed and stated at estimated fair value. Asia GA AUM is comprised of Asia GA total investments, the portion of the Asia GA investment portfolio classified within assets held-for-sale and cash and cash equivalents, excluding policy loans, contractholder-directed equity securities, fair value option securities and certain other invested assets, as substantially all of these assets are not actively managed in MetLife’s Asia GA investment portfolio. Mortgage loans (including commercial, agricultural and residential) and real estate equity (including real estate and real estate joint ventures) included in Asia GA AUM (at net asset value, net of deduction for encumbering debt) have been adjusted from carrying value to estimated fair value. At the segment level, intersegment balances (intercompany activity, primarily related to investments in subsidiaries, that eliminate at the MetLife consolidated level) are excluded from Asia GA AUM.

Asia GA AUM (at amortized cost) excludes the following adjustments: (i) unrealized gain (loss) on investments carried at estimated fair value and (ii) adjustments from carrying value to estimated fair value on mortgage loans (including commercial, agricultural and residential) and real estate and real estate joint ventures. Asia GA AUM (at amortized cost) is presented net of related allowance for credit loss.
Other items
The following additional information is relevant to an understanding of our performance results:
Statistical sales information for Latin America, Asia and EMEA: calculated using 10% of single-premium deposits (mainly from retirement products such as variable annuity, fixed annuity and pensions), 20% of single-premium deposits from credit insurance and 100% of annualized full-year premiums and fees from recurring-premium policy sales of all products (mainly from risk and protection products such as individual life, accident & health and group). Sales statistics do not correspond to revenues under GAAP, but are used as relevant measures of business activity.
A-8

METLIFE
ACRONYMS
 
AOCI Accumulated other comprehensive income (loss)
DAC Deferred policy acquisition costs
DPL Deferred profit liabilities
EMEA Europe, the Middle East and Africa
FCTA Foreign currency translation adjustments
GA General account
GA AUM General account assets under management
GAAP Accounting principles generally accepted in the United States of America
GICs Guaranteed interest contracts
GMIB Guaranteed minimum income benefits
NAIC National Association of Insurance Commissioners
NDGL Net derivative gains (losses)
NIGL Net investment gains (losses)
NRSRO Nationally Recognized Statistical Rating Organization
PAB Policyholder account balances
PBC Policyholder benefits and claims
PDO Policyholder dividend obligation
PRT Pension risk transfers
QFS Quarterly financial supplement
VIE Variable interest entity
VOBA Value of business acquired
A-9


image0a45.jpg
navigatinglifetogethera04a.jpg

EX-99.3 4 q12023totalaum05032023wi.htm EX-99.3 q12023totalaum05032023wi











EX-99.4 5 ex9941q23supplementalsli.htm EX-99.4 ex9941q23supplementalsli
1Q23 Supplemental Slides1 John McCallion Chief Financial Officer Exhibit 99.4 1 These slides highlight information in MetLife, Inc.'s earnings release, quarterly financial supplement and other prior public disclosures. Financial results in this presentation reflect LDTI accounting, pursuant to Financial Accounting Standards Board Accounting Standards Update No. 2018-12, which became effective on January 1, 2023. For more information, refer to "Explanatory Note on Non-GAAP and Other Financial Information."


 
2 Table of contents Topic Page No. Net income (loss) to adjusted earnings 3 Adjusted earnings, ex. total notable items, by segment 4 Variable investment income (VII) 5 Investments 7 Direct expense ratio 11 Cash & capital 12 Appendix 13


 
3 Net income (loss) to adjusted earnings 1Q23 (post-tax) $ in millions $ per share1 Net Income (Loss) $14 $0.02 Less: Net Investment Gains (Losses) (540) (0.69) Net Derivative Gains (Losses) (71) (0.09) Market Risk Benefit Gains (Losses) (149) (0.19) Investment Hedge Adjustments (209) (0.27) Other (201) (0.26) Adjusted Earnings $1,184 $1.52 1 The per share data for each item is calculated on a standalone basis and may not sum to the total.


 
4 ($ in millions - except per share data) 1Q23 1Q22 % Change % Change (Constant Rate) Key Drivers1 Favorable Unfavorable Group Benefits $307 $117 162% Underwriting Margins Retirement and Income Solutions 400 546 (27%) Investment Margins U.S. 707 663 7% Asia 280 599 (53%) (52%) Investment Margins Latin America 215 135 59% 51% Underwriting Margins; Volume Growth EMEA 60 55 9% 30% Investment Margins; Volume Growth MetLife Holdings 158 348 (55%) Investment Margins Corporate & Other (236) (105) Investment Margins Adjusted Earnings ex. Total Notable Items $1,184 $1,695 (30%) (29%) Adjusted EPS ex. Total Notable Items $1.52 $2.04 (25%) (25%) Adjusted earnings, ex. total notable items, by segment 1 To be discussed on MetLife, Inc.'s first quarter 2023 earnings conference call and audio webcast.


 
5 $24 ($44) $1,185 $389 ($53) 1Q22 2Q22 3Q22 4Q22 1Q23 1Q23 VII driven by lower venture capital and real estate returns1 ($ in millions - pre-tax) Private Equity Other 1 Quarterly target VII range of $500 million, based on full year 2023 guidance range of ~ $2.0 billion. $0


 
6 ($ in millions - post-tax1) 1Q22 2Q22 3Q22 4Q22 1Q23 Group Benefits $12 $7 $(1) $3 $— Retirement and Income Solutions 277 75 (35) 5 (3) U.S. 289 82 (36) 8 (3) Asia 288 101 (18) 4 (25) Latin America 16 16 — (3) (2) EMEA — — — — — MetLife Holdings 208 85 (21) 12 2 Corporate & Other 135 23 33 (1) (7) Total Variable Investment Income $936 $307 $(42) $20 $(35) 1 Assumes a 21% U.S. statutory tax rate. VII by segment


 
7 FY2020 FY2021 FY2022 1Q22 1Q23 Strong recurring income supported by higher interest rates and asset growth ($ in billions) Recurring income VII Net Investment Income1 $16.7 $3.8 $16.1 $5.7 $1.2 Roll Off vs. Reinvestment $15.6 $1.5 $1.2 New Money Yield Roll Off Yield 10-Year Treasury Yield 1Q20 3Q20 1Q21 3Q21 1Q22 3Q22 1Q23 0% 1% 2% 3% 4% 5% 6% 7% $4.6 5.82% 4.59% 3.47% 1 As reported, on an adjusted basis. $17.3 $21.3 $18.2 $5.0 $4.7


 
8 Global investment portfolio: High quality & resilient 1Q23 General Account AUM1 Highlights 1 General Account (GA) Assets Under Management (AUM). At estimated fair value. 2 Includes cash equivalents. 3 Represents the respective public and private portion of Investment Grade Corporate and Below Investment Grade Corporate. Public Credit includes Rule 144A securities and syndicated bank loan investments. 4 Represents Foreign Government and U.S. Government and Agency. 5 Includes common & preferred stock. 6 Real estate equity fair value of $18.1 billion and carrying value of $11.7 billion. 20% 19% 15% 13% 4% 3% 5% $424B • Large, diversified global portfolio • Disciplined asset-liability management • Prudent underwriting and risk management • Well positioned for uncertain environments • Unrealized gains in real estate equity of $6.4 billion6 • Favorable loss history over time Cash and Short-Term2 Public Credit3 Total Mortgage Loans Government and Agency4 Private Credit3 Structured Products Commercial Loans (Office) 8% 5% Commercial Loans (ex. Office) Agricultural Loans Residential Loans 3% 4% 1% Real Estate Equity Alternatives Other5


 
9 High quality commercial mortgage portfolio¹ • Diversified geographically and by property type • Concentrated in high-quality assets and in larger, primary markets • 58% average Loan-to-Value (LTV) and 2.4x average Debt Service Coverage Ratio (DSCR) • Commercial mortgage CECL2 allowance for credit loss of $319 million • Delinquency rate of 5 basis points • Only 14% of maturities scheduled in 2023 with 36% resolved through 4/30/23 1 At March 31, 2023. 2 Current expected credit loss (CECL). 3Amortized cost value as of March 31, 2023, prior to allowance for credit loss and excluding joint venture investments. LTV and DSCR Matrix $53.7 Billion3 LTV >1.2x 1.0-1.2x <1.0x Total <65% 70.4% 3.2% 3.3% 76.9% 65-75% 14.9% 1.4% 0.9% 17.2% 76-80% 1.9% 0.4% 0.5% 2.8% >80% 1.8% 0.9% 0.4% 3.1% Total 89.0% 5.9% 5.1% 100.0%


 
10 Office commercial mortgage loan portfolio • Office CML1 exposure $21 billion, or 4.9% of GA AUM • High quality portfolio; 89% of portfolio is collateralized by Class A properties • Average LTV of 57% and DSCR of 2.4x • Geographically diverse across international and U.S. markets • Reduced office CML exposure from 50% in 2016 to 39% as of 3/31/23 • Only 19% of maturities scheduled in 2023 with 36% resolved through 4/30/23 19.4% 9.3% 13.4% 14.0% 14.0% 29.9% 2023 2024 2025 2026 2027 2028+ Scheduled Maturities (% of Office CML Portfolio) 1Commercial mortgage loan (CML). Majority of Loans Low LTV and High DSCR LTV >1.2x 1.0x-1.2x <1.0x Total <65% 76.4% 1.9% 5.0% 83.3% 65-75% 11.4% 0.5% 0.5% 12.4% 76-80% 1.4% —% —% 1.4% >80% 2.0% 0.1% 0.8% 2.9% Total 91.2% 2.5% 6.3% 100.0%


 
11 11.9% 12.2% 12.4% 13.5% 12.0% 1Q22 2Q22 3Q22 4Q22 1Q23 1 Direct expense ratio, excluding total notable items related to direct expenses and pension risk transfers (PRT). 12.6% Annual Target 1Q23 direct expense ratio1 of 12.0%, below 12.6% annual target


 
12 Holding Company Cash1 $5.4 $4.2 $4.5 $5.2 $5.4 $4.2 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 Cash & capital 1 Includes cash and liquid assets at MetLife, Inc. and other holding companies at quarter-end. 2 Includes MetLife, Inc.'s principal U.S. insurance subsidiaries, excluding American Life Insurance Company. 3 MetLife calculates RBC annually as of December 31 and, accordingly, the calculation does not reflect conditions and factors occurring after the year end. 4 Includes MetLife, Inc.'s principal U.S. insurance subsidiaries, excluding American Life Insurance Company for both periods. $3.0B to $4.0B Cash Buffer Capital • Share repurchases of $0.8 billion in 1Q23 – $223 million shares repurchased in April 2023 • 2022 Combined NAIC Risk-Based Capital ratio2,3 of 367%, above 360% target • Expected total U.S. Statutory Adjusted Capital4 of $17.7 billion at 3/31/23, down 3% from 12/31/22 • Expected Japan Solvency Margin ratio of ~725% at 3/31/23 ($ in billions)


 
Appendix


 
14 GAAP Consolidated Statement of Operations (LDTI Basis) FY2022 FY2021 (In millions) Revenues Premiums $ 48,510 $ 41,152 Universal life and investment-type product policy fees 5,225 5,244 Net investment income 15,916 21,395 Other revenues 2,630 2,619 Net investment gains (losses) (1,260) 1,543 Net derivative gains (losses) (2,251) (3,257) Total revenues 68,770 68,696 Expenses Policyholder benefits and claims 49,507 43,118 Policyholder liability remeasurement (gains) losses 114 (172) Market risk benefit remeasurement (gains) losses (3,674) (1,237) Interest credited to policyholder account balances 3,894 5,571 Policyholder dividends 706 880 Amortization of DAC and VOBA 1,831 2,037 Amortization of negative VOBA (29) (35) Interest expense on debt 938 920 Other expenses, net of capitalization of DAC 9,119 9,096 Total expenses 62,406 60,178 Income (loss) before provision for income tax 6,364 8,518 Provision for income tax expense (benefit) 1,062 1,642 Net income (loss) 5,302 6,876 Less: Net income (loss) attributable to noncontrolling interests 18 21 Net income (loss) attributable to MetLife, Inc. 5,284 6,855 Less: Preferred stock dividends 185 195 Preferred stock redemption premium — 6 Net income (loss) available to MetLife, Inc.'s common shareholders $ 5,099 $ 6,654


 
15 Reconciliation of Net Income (Loss) Available to MetLife, Inc.'s Common Shareholders to Adjusted Earnings Available to Common Shareholders (LDTI Basis) FY2022 FY2021 (In millions) Net Income (loss) available to MetLife, Inc.'s common shareholders $ 5,099 $ 6,654 Adjustments from net income (loss) available to MetLife, Inc.'s common shareholders to adjusted earnings available to common shareholders: Less: Net investment gains (losses) (1,260) 1,543 Less: Net derivative gains (losses) (2,251) (3,257) Less: Market risk benefit remeasurement gains (losses) 3,674 1,237 Less: Other adjustments to net income (loss) (1,419) (1,039) Less: Provision for income tax (expense) benefit 580 294 Add: Net income (loss) attributable to noncontrolling interests 18 21 Add: Preferred stock redemption premium — 6 Adjusted earnings available to common shareholders 5,793 7,903 Less: Total notable items 89 293 Adjusted earnings available to common shareholders, excluding total notable items $ 5,704 $ 7,610


 
16 Segment Results - Adjusted Earnings Available to Common Shareholders and Adjusted Premiums, Fees and Other Revenues (LDTI Basis) FY2022 U.S. Group Benefits Retirement & Income Solutions Asia Latin America EMEA MetLife Holdings Corporate & Other (In millions) Adjusted earnings available to common shareholders $ 2,967 $ 1,332 $ 1,635 $ 1,617 $ 729 $ 249 $ 1,031 $ (800) Less: Total notable items 79 — 79 (32) 1 15 26 — Adjusted earnings available to common shareholders, excluding total notable items $ 2,888 $ 1,332 $ 1,556 $ 1,649 $ 728 $ 234 $ 1,005 $ (800) Adjusted premiums, fees and other revenues $ 37,580 $ 23,266 $ 14,314 $ 7,346 $ 4,438 $ 2,281 $ 4,123 $ 382 Less: Pension risk transfers (PRT) 12,219 — 12,219 — — — — — Adjusted premiums, fees and other revenues, excluding PRT $ 25,361 $ 23,266 $ 2,095 $ 7,346 $ 4,438 $ 2,281 $ 4,123 $ 382 FY2021 U.S. Group Benefits Retirement & Income Solutions Asia Latin America EMEA MetLife Holdings Corporate & Other (In millions) Adjusted earnings available to common shareholders $ 3,054 $ 463 $ 2,591 $ 2,517 $ 274 $ 306 $ 2,103 $ (351) Less: Total notable items 14 — 14 56 6 — 11 206 Adjusted earnings available to common shareholders, excluding total notable items $ 3,040 $ 463 $ 2,577 $ 2,461 $ 268 $ 306 $ 2,092 $ (557) Adjusted premiums, fees and other revenues $ 28,176 $ 22,543 $ 5,633 $ 8,120 $ 3,790 $ 2,708 $ 4,513 $ 457 Less: Pension risk transfers (PRT) 3,513 — 3,513 — — — — — Adjusted premiums, fees and other revenues, excluding PRT $ 24,663 $ 22,543 $ 2,120 $ 8,120 $ 3,790 $ 2,708 $ 4,513 $ 457


 
17 Cautionary Statement on Forward-Looking Statements The forward-looking statements in this presentation, using words such as “anticipate,” “are confident,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “grow,” “guidance,” “if,” “intend,” “likely,” “long-term,” “may,” “near-term,” “ongoing,” “outlook,” “plan,” “potential,” “project,” “remain,” “should,” “target,” “to be,” “will,” and “would” are based on assumptions and expectations that involve risks and uncertainties, including the “Risk Factors” MetLife, Inc. describes in its U.S. Securities and Exchange Commission filings. MetLife’s future results could differ, and it does not undertake any obligation to publicly correct or update any of these statements.


 
18 Explanatory Note on Non-GAAP and Other Financial Information Any references in this presentation (except in this Explanatory Note on Non-GAAP Financial Information and Reconciliations) to: Should be read as, respectively: (i) net income (loss); (i) net income (loss) available to MetLife, Inc.’s common shareholders; (ii) net income (loss) per share; (ii) net income (loss) available to MetLife, Inc.’s common shareholders per diluted common share; (iii) adjusted earnings; and (iii) adjusted earnings available to common shareholders; and (iv) adjusted earnings per share; (iv) adjusted earnings available to common shareholders per diluted common share; In this presentation, MetLife presents certain measures of its performance on a consolidated and segment basis that are not calculated in accordance with accounting principles generally accepted in the United States of America (GAAP). MetLife believes that these non-GAAP financial measures enhance the understanding for MetLife and its investors of MetLife's performance by highlighting the results of operations and the underlying profitability drivers of the business. Segment-specific financial measures are calculated using only the portion of consolidated results attributable to that specific segment. The following non-GAAP financial measures should not be viewed as substitutes for the most directly comparable financial measures calculated in accordance with GAAP: Non-GAAP financial measures: Comparable GAAP financial measures: (i) adjusted premiums, fees and other revenues; (i) premiums, fees and other revenues; (ii) adjusted premiums, fees and other revenues, excluding pension risk transfers (PRT); (ii) premiums, fees and other revenues; (iii) adjusted capitalization of deferred policy acquisition costs (DAC); (iii) capitalization of DAC; (iv) adjusted earnings available to common shareholders; (iv) net income (loss) available to MetLife, Inc.’s common shareholders; (v) adjusted earnings available to common shareholders, excluding total notable items; (v) net income (loss) available to MetLife, Inc.’s common shareholders; (vi) adjusted earnings available to common shareholders per diluted common share; (vi) net income (loss) available to MetLife, Inc.’s common shareholders per diluted common share; (vii) adjusted earnings available to common shareholders, excluding total notable items, per diluted common share; (vii) net income (loss) available to MetLife, Inc.’s common shareholders per diluted common share; (viii) adjusted other expenses; (viii) other expenses; (ix) adjusted other expenses, net of adjusted capitalization of DAC; (ix) other expenses, net of capitalization of DAC; (x) adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses; (x) other expenses, net of capitalization of DAC; (xi) adjusted expense ratio; (xi) expense ratio; (xii) adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT; (xii) expense ratio; (xiii) direct expenses; (xiii) other expenses; (xiv) direct expenses, excluding total notable items related to direct expenses; (xiv) other expenses; (xv) direct expense ratio; and (xv) expense ratio; and (xvi) direct expense ratio, excluding total notable items related to direct expenses and PRT. (xvi) expense ratio.


 
19 MetLife’s definitions of non-GAAP and other financial measures discussed in this presentation may differ from those used by other companies: Adjusted earnings and related measures • adjusted earnings; • adjusted earnings available to common shareholders; • adjusted earnings available to common shareholders, excluding total notable items; • adjusted earnings available to common shareholders per diluted common share; • adjusted earnings available to common shareholders, excluding total notable items per diluted common share; and • adjusted earnings available to common shareholders on a constant currency basis. These measures are used by management to evaluate performance and allocate resources. Consistent with GAAP guidance for segment reporting, adjusted earnings and components of, or other financial measures based on, adjusted earnings are also MetLife’s GAAP measures of segment performance. Adjusted earnings and other financial measures based on adjusted earnings are also the measures by which MetLife senior management’s and many other employees’ performance is evaluated for the purposes of determining their compensation under applicable compensation plans. Adjusted earnings and other financial measures based on adjusted earnings allow analysis of MetLife's performance relative to its business plan and facilitate comparisons to industry results. Effective January 1, 2023, MetLife adopted ASU 2018-12, Financial Services - Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts, as amended ("LDTI"), with a transition date of January 1, 2021, which impacted the calculation of adjusted earnings. With the the adoption of LDTI, the measurement model was simplified for DAC and VOBA, and most embedded derivatives were reclassified as market risk benefits. As a result, MetLife updated its calculation of adjusted earnings to remove certain adjustments related to the amortization of DAC, VOBA and related intangibles and adjusted for changes in measurement of certain guarantees. Under LDTI, adjusted earnings excludes changes in fair value associated with market risk benefits, changes in discount rates on certain annuitization guarantees, losses at contract inception for certain single premium business, and asymmetrical accounting associated with in-force reinsurance. All periods presented herein reflect the updated calculation of adjusted earnings. Adjusted earnings is defined as adjusted revenues less adjusted expenses, net of income tax. Adjusted earnings available to common shareholders is defined as adjusted earnings less preferred stock dividends. Adjusted revenues and adjusted expenses These financial measures, along with the related adjusted premiums, fees and other revenues, focus on our primary businesses principally by excluding the impact of (i) market volatility which could distort trends, (ii) asymmetrical and non-economic accounting, and (iii) revenues and costs related to divested businesses, non-core products and certain entities required to be consolidated under GAAP. Also, these measures exclude results of discontinued operations under GAAP. Market volatility can have a significant impact on the Company’s financial results. Adjusted earnings excludes net investment gains (losses), net derivative gains (losses), market risk benefits remeasurement gains (losses) and goodwill impairments. Further, policyholder benefits and claims exclude (i) changes in the discount rate on certain annuitization guarantees accounted for as additional liabilities and (ii) market value adjustments. Explanatory Note on Non-GAAP and Other Financial Information (Continued) Any of these financial measures shown on a constant currency basis reflect the impact of changes in foreign currency exchange rates and are calculated using the average foreign currency exchange rates for the most recent period. As a result, comparable prior period amounts are updated each period to reflect the most recent period average foreign currency exchange rates. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in this presentation and in this period’s earnings news release, which is available at www.metlife.com.


 
20 Explanatory Note on Non-GAAP and Other Financial Information (Continued) Asymmetrical and non-economic accounting adjustments are made to the line items indicated in calculating adjusted earnings: • Net investment income includes earned income on derivatives and amortization of premium on derivatives that are hedges of investments or that are used to replicate certain investments, but do not qualify for hedge accounting treatment ("Investment hedge adjustments"). • Other revenues include settlements of foreign currency earnings hedges. • Policyholder benefits and claims excludes (i) amortization of basis adjustments associated with de-designated fair value hedges of future policy benefits, (ii) inflation-indexed benefit adjustments associated with contracts backed by inflation- indexed investments, and (iii) non-economic losses incurred at contract inception for certain single premium annuity business. These losses are amortized into adjusted earnings within policyholder benefits and claims over the estimated lives of the contracts. • Interest credited to policyholder account balances excludes amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass-through adjustments. Divested businesses are those that have been or will be sold or exited by MetLife but do not meet the discontinued operations criteria under GAAP. Divested businesses also include the net impact of transactions with exited businesses that have been eliminated in consolidation under GAAP and costs relating to businesses that have been or will be sold or exited by MetLife that do not meet the criteria to be included in results of discontinued operations under GAAP. Other adjustments are made to the line items indicated in calculating adjusted earnings: • Net investment income and interest credited to policyholder account balances excludes certain amounts related to contractholder-directed equity securities ("Unit-linked contract income") and ("Unit-linked contract costs"). • Other revenues include fee revenue on synthetic GICs accounted for as freestanding derivatives. • Other revenues exclude and other expenses include fees received in connection with services provided under transition service agreements. • Other expenses exclude (i) implementation of new insurance regulatory requirements and other costs, and (ii) acquisition, integration and other related costs. Other expenses include (i) deductions for net income attributable to noncontrolling interests, and (ii) benefits accrued on synthetic GICs accounted for as freestanding derivatives. Adjusted earnings also excludes the recognition of certain contingent assets and liabilities that could not be recognized at acquisition or adjusted for during the measurement period under GAAP business combination accounting guidance. The tax impact of the adjustments mentioned above are calculated net of the U.S. or foreign statutory tax rate, which could differ from MetLife's effective tax rate. Additionally, the provision for income tax (expense) benefit also includes the impact related to the timing of certain tax credits, as well as certain tax reforms. In addition, adjusted earnings available to common shareholders excludes the impact of preferred stock redemption premium, which is reported as a reduction to net income (loss) available to MetLife, Inc.’s common shareholders. Investment portfolio gains (losses) and derivative gains (losses) These are measures of investment and hedging activity. Investment portfolio gains (losses) principally excludes amounts that are reported within net investment gains (losses) but do not relate to the performance of the investment portfolio, such as gains (losses) on sales and divestitures of businesses, as well as investment portfolio gains (losses) of divested businesses. Derivative gains (losses) principally excludes earned income on derivatives and amortization of premium on derivatives, where such derivatives are either hedges of investments or are used to replicate certain investments, and where such derivatives do not qualify for hedge accounting. This earned income and amortization of premium is reported within adjusted earnings and not within derivative gains (losses).


 
21 Explanatory Note on Non-GAAP and Other Financial Information (Continued) Return on equity and related measures • Total MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA: Total MetLife, Inc.’s common stockholders’ equity, excluding the net unrealized investment gains (losses), future policy benefits discount rate remeasurement gains (losses), market risk benefits instrument-specific credit risk remeasurement gains (losses), defined benefit plans adjustment, components of AOCI, net of income tax. • Total MetLife, Inc.’s common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA): Total MetLife, Inc.’s common stockholders’ equity, excluding the net unrealized investment gains (losses), future policy benefits discount rate remeasurement gains (losses), market risk benefits instrument-specific credit risk remeasurement gains (losses), defined benefit plans adjustment, components of AOCI, and total notable items, net of income tax. • Return on MetLife, Inc.’s common stockholders’ equity: net income (loss) available to MetLife, Inc.’s common shareholders divided by MetLife, Inc.'s average common stockholders’ equity. • Adjusted return on MetLife, Inc.’s common stockholders’ equity: adjusted earnings available to common shareholders divided by MetLife, Inc.'s average common stockholders’ equity. • Adjusted return on MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA: adjusted earnings available to common shareholders divided by MetLife, Inc.'s average common stockholders’ equity, excluding AOCI other than FCTA. • Adjusted return on MetLife, Inc.’s common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA): adjusted earnings available to common shareholders, excluding total notable items, divided by MetLife, Inc.'s average common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA). The above measures represent a level of equity consistent with the view that, in the ordinary course of business, we do not plan to sell most investments for the sole purpose of realizing gains or losses. Expense ratio, direct expense ratio, adjusted expense ratio and related measures • Expense ratio: other expenses, net of capitalization of DAC, divided by premiums, fees and other revenues. • Direct expense ratio: adjusted direct expenses, divided by adjusted premiums, fees and other revenues. • Direct expense ratio, excluding total notable items related to direct expenses and PRT: adjusted direct expenses, excluding total notable items related to direct expenses, divided by adjusted premiums, fees and other revenues, excluding PRT. • Adjusted expense ratio: adjusted other expenses, net of adjusted capitalization of DAC, divided by adjusted premiums, fees and other revenues. • Adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT: adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses, divided by adjusted premiums, fees and other revenues, excluding PRT. General Account (GA) assets under management (GA AUM) GA AUM is used by MetLife to describe assets in its general account GA investment portfolio which are actively managed and stated at estimated fair value. GA AUM is comprised of GA total investments, the portion of the GA investment portfolio classified within assets held-for-sale, and cash and cash equivalents, excluding policy loans, contractholder-directed equity securities, fair value option securities and certain other invested assets, as substantially all of these assets are not actively managed in MetLife’s GA investment portfolio. Mortgage loans (including commercial, agricultural and residential) and real estate equity (including real estate and real estate joint ventures) included in GA AUM (at net asset value, net of deduction for encumbering debt) have been adjusted from carrying value to estimated fair value. Classification of GA AUM by sector is based on the nature and characteristics of the underlying investments which can vary from how they are classified under GAAP. Accordingly, the underlying investments within certain real estate and real estate joint ventures that are primarily commercial mortgage loans (at net asset value, net of deduction for encumbering debt) have been reclassified to exclude them from real estate equity and include them as commercial mortgage loans. Asia GA AUM and related measures Asia GA AUM is used by MetLife to describe assets in its Asia GA investment portfolio which are actively managed and stated at estimated fair value. Asia GA AUM is comprised of Asia GA total investments, the portion of the Asia GA investment portfolio classified within assets held-for-sale and cash and cash equivalents, excluding policy loans, contractholder-directed equity securities, fair value option securities and certain other invested assets, as substantially all of these assets are not actively managed in MetLife’s Asia GA investment portfolio. Mortgage loans (including commercial, agricultural and residential) and real estate equity (including real estate and real estate joint ventures) included in Asia GA AUM (at net asset value, net of deduction for encumbering debt) have been adjusted from carrying value to estimated fair value. At the segment level, intersegment balances (intercompany activity, primarily related to investments in subsidiaries, that eliminate at the MetLife consolidated level) are excluded from Asia GA AUM. Asia GA AUM (at amortized cost) excludes the following adjustments: (i) unrealized gain (loss) on investments carried at estimated fair value and (ii) adjustments from carrying value to estimated fair value on mortgage loans (including commercial, agricultural and residential) and real estate and real estate joint ventures. Asia GA AUM (at amortized cost) is presented net of related allowance for credit loss.


 
22 Explanatory Note on Non-GAAP and Other Financial Information (Continued) Statistical sales information: • U.S.: ◦ Group Benefits: calculated using 10% of single premium deposits and 100% of annualized full-year premiums and fees from recurring premium policy sales of all products. ◦ Retirement and Income Solutions: calculated using 10% of single premium deposits and 100% of annualized full-year premiums and fees only from recurring premium policy sales of specialized benefit resources and corporate-owned life insurance. • Latin America, Asia and EMEA: calculated using 10% of single-premium deposits (mainly from retirement products such as variable annuity, fixed annuity and pensions), 20% of single-premium deposits from credit insurance and 100% of annualized full-year premiums and fees from recurring-premium policy sales of all products (mainly from risk and protection products such as individual life, accident & health and group). Sales statistics do not correspond to revenues under GAAP, but are used as relevant measures of business activity. The following additional information is relevant to an understanding of MetLife’s performance results and outlook: • Volume growth, as discussed in the context of business growth, is the period over period percentage change in adjusted earnings available to common shareholders attributable to adjusted premiums, fees and other revenues and assets under management levels, applying a model in which certain margins and factors are held constant. The most significant of such items are underwriting margins, investment margins, changes in equity market performance, expense margins and the impact of changes in foreign currency exchange rates. • Notable items reflect the unexpected impact of events that affect MetLife’s results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results. Notable items represent a positive (negative) impact to adjusted earnings available to common shareholders. • Holding company cash and liquid assets are held by MetLife, Inc. collectively with other MetLife holding companies and include cash and cash equivalents, short term investments and publicly traded securities excluding assets that are pledged or otherwise committed. Assets pledged or otherwise committed include amounts received in connection with securities lending, repurchase agreements, derivatives, regulatory deposits, the collateral financing arrangement, funding agreements and secured borrowings, as well as amounts held in the closed block.


 
23 Reconciliation of Net Income (Loss) Available to MetLife, Inc.'s Common Shareholders to Adjusted Earnings Available to Common Shareholders 1Q23 1Q22 Earnings Per Weighted Average Common Share Diluted1 Earnings Per Weighted Average Common Share Diluted1 (In millions, except per share data) Net Income (loss) available to MetLife, Inc.'s common shareholders $ 14 $ 0.02 $ 1,571 $ 1.89 Adjustments from net income (loss) available to MetLife, Inc.'s common shareholders to adjusted earnings available to common shareholders: Less: Net investment gains (losses) (684) (0.88) (517) (0.62) Less: Net derivative gains (losses) (90) (0.12) (951) (1.15) Less: Market risk benefit remeasurement gains (losses) (188) (0.24) 1,440 1.73 Less: Other adjustments to net income (loss) (383) (0.48) (271) (0.32) Less: Provision for income tax (expense) benefit 180 0.23 180 0.22 Add: Net income (loss) attributable to noncontrolling interests 5 0.01 5 0.01 Adjusted earnings available to common shareholders 1,184 1.52 1,695 2.04 Less: Total notable items — — — — Adjusted earnings available to common shareholders, excluding total notable items $ 1,184 1.52 $ 1,695 $ 2.04 Adjusted earnings available to common shareholders on a constant currency basis $ 1,184 $ 1.52 $ 1,675 $ 2.02 Adjusted earnings available to common shareholders, excluding total notable items, on a $ 1,184 $ 1.52 $ 1,675 $ 2.02 constant currency basis Weighted average common shares outstanding - diluted 781.2 830.5 1Adjusted earnings available to common shareholders, excluding total notable items, per diluted common share is calculated on a standalone basis and may not equal (i) adjusted earnings available to common shareholders per diluted common share, less (ii) total notable items per diluted common share.


 
24 Reconciliation to Adjusted Earnings Available to Common Shareholders, Excluding Total Notable Items 1Q23 U.S.1 Group Benefits1 Retirement & Income Solutions1 Asia Latin America EMEA MetLife Holdings1 Corporate & Other1 (In millions) Adjusted earnings available to common shareholders $ 707 $ 307 $ 400 $ 280 $ 215 $ 60 $ 158 $ (236) Less: Total notable items — — — — — — — — Adjusted earnings available to common shareholders, excluding total notable items $ 707 $ 307 $ 400 $ 280 $ 215 $ 60 $ 158 $ (236) Adjusted earnings available to common shareholders on a constant currency basis $ 280 $ 215 $ 60 Adjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis $ 280 $ 215 $ 60 1Q22 U.S.1 Group Benefits1 Retirement & Income Solutions1 Asia Latin America EMEA MetLife Holdings1 Corporate & Other1 (In millions) Adjusted earnings available to common shareholders $ 663 $ 117 $ 546 $ 599 $ 135 $ 55 $ 348 $ (105) Less: Total notable items — — — — — — — — Adjusted earnings available to common shareholders, excluding total notable items $ 663 $ 117 $ 546 $ 599 $ 135 $ 55 $ 348 $ (105) Adjusted earnings available to common shareholders on a constant currency basis $ 581 $ 142 $ 46 Adjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis $ 581 $ 142 $ 46 1Results on a constant currency basis are not included as constant currency impact is not significant.


 
25 Reconciliation of Net Investment Income to Adjusted Net Investment Income FY2020 FY2021 FY2022 1Q22 1Q23 (In millions) Net investment income $ 17,117 $ 21,395 $ 15,916 $ 4,284 $ 4,645 Less: Adjustments to net investment income Investment hedge adjustments (815) (895) (976) (215) (264) Unit-linked contract income 568 952 (1,298) (498) 303 Other adjustments (10) (9) (10) (6) — Divested business 46 67 11 11 — Adjusted net investment income $ 17,328 $ 21,280 $ 18,189 $ 4,992 $ 4,606


 
26 Reconciliation of Premiums, Fees and Other Revenues to Adjusted Premiums, Fees and Other Revenues 1Q22 2Q22 3Q22 4Q22 1Q23 (In millions) Premiums, fees and other revenues $ 12,589 $ 13,543 $ 19,335 $ 10,898 $ 11,517 Less: Adjustments to premiums, fees and other revenues: Asymmetrical and non-economic accounting — — — — — Other adjustments 47 48 40 25 (3) Divested business 55 — — — — Adjusted premiums, fees and other revenues $ 12,487 $ 13,495 $ 19,295 $ 10,873 $ 11,520


 
27 Expense Detail and Ratios (In millions, except ratio data) 1Q22 2Q22 3Q22 4Q22 1Q23 Reconciliation of Capitalization of DAC to Adjusted Capitalization of DAC Capitalization of DAC $ (652) $ (637) $ (626) $ (699) $ (718) Less: Divested businesses (11) — — — — Adjusted capitalization of DAC $ (641) $ (637) $ (626) $ (699) $ (718) Reconciliation of Other Expenses to Adjusted Other Expenses Other expenses $ 2,912 $ 2,868 $ 2,875 $ 3,078 $ 3,057 Less Adjustments to other expenses: Other adjustments 47 60 47 37 16 Divested businesses 32 8 13 21 11 Adjusted other expenses $ 2,833 $ 2,800 $ 2,815 $ 3,020 $ 3,030 Other Detail and Ratios Other expenses, net of capitalization of DAC $ 2,260 $ 2,231 $ 2,249 $ 2,379 $ 2,339 Premiums, fees and other revenues $ 12,589 $ 13,543 $ 19,335 $ 10,898 $ 11,517 Expense ratio 18.0 % 16.5 % 11.6 % 21.8 % 20.3 % Direct expenses $ 1,332 $ 1,335 $ 1,342 $ 1,481 $ 1,387 Less: Total notable items related to direct expenses — — — — — Direct expenses, excluding total notable items related to direct expenses $ 1,332 $ 1,335 $ 1,342 $ 1,481 $ 1,387 Adjusted other expenses $ 2,833 $ 2,800 $ 2,815 $ 3,020 $ 3,030 Adjusted capitalization of DAC (641) (637) (626) (699) (718) Adjusted other expenses, net of adjusted capitalization of DAC $ 2,192 $ 2,163 $ 2,189 $ 2,321 $ 2,312 Less: Total notable items related to adjusted other expenses — — — — — Adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses $ 2,192 $ 2,163 $ 2,189 $ 2,321 $ 2,312 Adjusted premiums, fees and other revenues $ 12,487 $ 13,495 $ 19,295 $ 10,873 $ 11,520 Less: PRT 1,258 2,564 8,466 (69) (21) Adjusted premiums, fees and other revenues, excluding PRT $ 11,229 $ 10,931 $ 10,829 $ 10,942 $ 11,541 Direct expense ratio 10.7 % 9.9 % 7.0 % 13.6 % 12.0 % Direct expense ratio, excluding total notable items related to direct expenses and PRT 11.9 % 12.2 % 12.4 % 13.5 % 12.0 % Adjusted expense ratio 17.6 % 16.0 % 11.3 % 21.3 % 20.1 % Adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT 19.5 % 19.8 % 20.2 % 21.2 % 20.0 %


 
28